@NP	Improving the regenerative potential	1
@NP	Improving	1
@NP	the regenerative potential	11
@NP	olfactory ensheathing cells	41
@NP	overexpressing prostacyclin synthetase	72
@NP	its application in spinal cord repair Abstract Background	115
@NP	its application	115
@NP	spinal cord repair Abstract Background	134
@NP	Olfactory ensheathing cells	175
@NP	OEC	204
@NP	specialized glia that ensheathe bundles of olfactory nerves	210
@NP	specialized glia	210
@NP	bundles of olfactory nerves	242
@NP	bundles	242
@NP	olfactory nerves	253
@NP	a favorable substrate for axonal regeneration	293
@NP	a favorable substrate	293
@NP	axonal regeneration	319
@NP	Grafting OEC to injured spinal cord	340
@NP	Grafting OEC	340
@NP	injured spinal cord	356
@NP	axonal regeneration	398
@NP	the functional recovery	427
@NP	an attempt to improve the growth-promoting properties of OEC	466
@NP	the growth-promoting properties of OEC	488
@NP	the growth-promoting properties	488
@NP	OEC	523
@NP	we	528
@NP	prostacyclin synthase -LRB- PGIS -RRB-	542
@NP	prostacyclin synthase	542
@NP	PGIS	565
@NP	OEC via adenoviral -LRB- Ad -RRB- gene transfer	574
@NP	OEC	574
@NP	adenoviral -LRB- Ad -RRB- gene transfer	582
@NP	Ad	594
@NP	the effect of OEC	625
@NP	the effect	625
@NP	OEC	639
@NP	enhanced prostacyclin synthesis in co-culture and in vivo	648
@NP	enhanced prostacyclin synthesis	648
@NP	co-culture	683
@NP	Prostacyclin	707
@NP	a vasodilator , platelet anti-aggregatory and cytoprotective agent	723
@NP	a vasodilator	723
@NP	platelet anti-aggregatory and cytoprotective agent	738
@NP	Results	790
@NP	OEC	808
@NP	high level of cyclooxygneases , but not PGIS	822
@NP	high level	822
@NP	cyclooxygneases , but not PGIS	836
@NP	cyclooxygneases	836
@NP	PGIS	861
@NP	Infection of AdPGIS to OEC	867
@NP	Infection	867
@NP	AdPGIS to OEC	880
@NP	AdPGIS	880
@NP	OEC	890
@NP	prostacyclin synthesis	921
@NP	either OEC or AdPGIS-OEC	966
@NP	OEC	973
@NP	AdPGIS-OEC	980
@NP	neuronal cells	992
@NP	OGD-induced damage	1025
@NP	The	1045
@NP	OEC	1058
@NP	further	1067
@NP	the transected cavity of thoracic spinal cord injured -LRB- SCI -RRB- rats	1091
@NP	the	1091
@NP	cavity of thoracic spinal cord injured -LRB- SCI -RRB- rats	1106
@NP	cavity	1106
@NP	thoracic spinal cord injured -LRB- SCI -RRB- rats	1116
@NP	thoracic spinal cord	1116
@NP	-LRB- SCI -RRB- rats	1145
@NP	SCI	1146
@NP	6 weeks	1160
@NP	significant functional recovery in hind limbs	1182
@NP	significant functional recovery	1182
@NP	hind limbs	1217
@NP	OEC or AdPGIS-OEC transplanted SCI rats compared with nontreated SCI rats	1240
@NP	OEC or AdPGIS-OEC	1240
@NP	SCI rats	1271
@NP	nontreated SCI rats	1294
@NP	10 -- 12 weeks postgraft	1318
@NP	10	1318
@NP	12 weeks postgraft	1321
@NP	12 weeks	1321
@NP	postgraft	1330
@NP	AdPGIS-OEC transplanted SCI rats	1341
@NP	AdPGIS-OEC	1341
@NP	SCI rats	1365
@NP	better motor restoration than OEC	1395
@NP	better motor restoration	1395
@NP	OEC	1425
@NP	transplanted SCI rats	1429
@NP	regenerating fiber tracts in the distal spinal cord stump	1464
@NP	regenerating fiber tracts	1464
@NP	the distal spinal cord stump	1493
@NP	40	1536
@NP	60 % of AdPGIS-OEC transplanted SCI rats	1539
@NP	60 %	1539
@NP	AdPGIS-OEC transplanted SCI rats	1546
@NP	AdPGIS-OEC	1546
@NP	SCI rats	1570
@NP	Conclusions	1580
@NP	synthesis of prostacyclin	1602
@NP	synthesis	1602
@NP	prostacyclin	1615
@NP	grafted OEC	1631
@NP	fiber tract regeneration and functional restoration in spinal cord injured rats	1652
@NP	fiber tract regeneration and functional restoration	1652
@NP	spinal cord injured rats	1707
@NP	spinal cord	1707
@NP	rats	1727
@NP	These results	1733
@NP	an important potential of prostacyclin	1755
@NP	an important potential	1755
@NP	prostacyclin	1781
@NP	OEC therapeutic properties that are relevant for neural transplant therapies	1809
@NP	OEC therapeutic properties	1809
@NP	neural transplant therapies	1858
@NP	Background Complete transection of the adult mammalian spinal cord	1888
@NP	Background Complete transection	1888
@NP	the adult mammalian spinal cord	1923
@NP	irreversible and permanent loss of motor and somatosensory function	1966
@NP	irreversible and permanent loss	1966
@NP	motor and somatosensory function	2001
@NP	the injury site -LSB- 1 -- 3 -RSB-	2040
@NP	the injury site	2040
@NP	1 -- 3	2057
@NP	The inhospitable environment and lack	2063
@NP	spontaneous regeneration of injured central axons	2104
@NP	spontaneous regeneration	2104
@NP	injured central axons	2132
@NP	permanent functional impairment	2162
@NP	the adult SCI victims -LSB- 4	2197
@NP	the adult SCI victims	2197
@NP	4	2220
@NP	6 -RSB-	2222
@NP	this	2235
@NP	the olfactory bulb	2258
@NP	The growth permissive olfactory bulbs	2278
@NP	The growth	2278
@NP	permissive olfactory bulbs	2289
@NP	the presence	2327
@NP	olfactory ensheathing cells -LRB- OEC -RRB-	2343
@NP	olfactory ensheathing cells	2343
@NP	OEC	2372
@NP	the distinct glia	2378
@NP	the primary olfactory nerve	2399
@NP	both Schwann cell-like and astrocyte-like characteristics -LSB- 7 -- 10 -RSB-	2432
@NP	Schwann cell-like and astrocyte-like characteristics	2437
@NP	Schwann	2437
@NP	cell-like and astrocyte-like characteristics	2445
@NP	7	2491
@NP	10 -RSB-	2493
@NP	The presence of OEC	2498
@NP	The presence	2498
@NP	OEC	2514
@NP	support	2540
@NP	growing axons	2558
@NP	olfactory sensory neurons	2575
@NP	the transition zone between PNS and CNS	2610
@NP	the transition zone	2610
@NP	PNS and CNS	2638
@NP	processes in the olfactory bulb	2661
@NP	processes	2661
@NP	the olfactory bulb	2674
@NP	inhibition -LSB- 9 -- 12 -RSB-	2701
@NP	inhibition	2701
@NP	9 -- 12	2713
@NP	Several groups	2720
@NP	OEC transplant	2745
@NP	axonal elongation	2773
@NP	different injured CNS regions -LSB- 13 -- 17 -RSB-	2794
@NP	different injured CNS regions	2794
@NP	13 -- 17	2825
@NP	implantation in the spinal cord	2839
@NP	implantation	2839
@NP	the spinal cord	2855
@NP	OEC	2872
@NP	a less severe host astrocyte response than Schwann cells	2884
@NP	a less severe host astrocyte response	2884
@NP	Schwann cells	2927
@NP	18 -RSB-	2942
@NP	OEC transplantation	2953
@NP	a promising treatment for spinal cord injury	2987
@NP	a promising treatment	2987
@NP	spinal cord injury	3013
@NP	the improvement of functional recovery	3042
@NP	the improvement	3042
@NP	functional recovery	3061
@NP	-LSB- 14 , 19 , 20 -RSB-	3092
@NP	Overexpression of neuroprotective genes	3106
@NP	Overexpression	3106
@NP	neuroprotective genes	3124
@NP	a promising strategy to promote regeneration of injured axon	3152
@NP	regeneration of injured axon	3184
@NP	regeneration	3184
@NP	injured axon	3200
@NP	an attempt to further increase the growth	3217
@NP	an attempt	3217
@NP	further increase the growth	3231
@NP	further increase	3231
@NP	the growth	3248
@NP	effect of OEC	3269
@NP	effect	3269
@NP	OEC	3279
@NP	the present study	3284
@NP	ex vivo adenovirus-mediated gene	3310
@NP	protacyclin synthase -LRB- PGIS -RRB-	3355
@NP	protacyclin synthase	3355
@NP	PGIS	3377
@NP	OEC	3386
@NP	prostacyclin synthesis	3404
@NP	Prostacyclin -LRB- prostaglandin -LRB- PG -RRB- I2 -RRB-	3428
@NP	Prostacyclin	3428
@NP	prostaglandin -LRB- PG -RRB- I2	3442
@NP	prostaglandin -LRB- PG -RRB-	3442
@NP	prostaglandin	3442
@NP	PG	3457
@NP	I2	3461
@NP	a primary vasodilator	3473
@NP	an inhibitor of leukocyte adhesion and platelet aggregation -LSB- 21 , 22 -RSB-	3502
@NP	an inhibitor	3502
@NP	leukocyte adhesion and platelet aggregation -LSB- 21	3518
@NP	leukocyte adhesion and platelet aggregation	3518
@NP	21	3563
@NP	PGI2	3572
@NP	the sequential action	3595
@NP	cyclooxygenase -LRB- COX -RRB-	3620
@NP	cyclooxygenase	3620
@NP	COX	3636
@NP	-1 or âˆ’ 2	3640
@NP	prostacyclin synthase	3653
@NP	arachidonic acid	3680
@NP	AA	3698
@NP	cellular phospholipids -LSB- 23 -RSB-	3727
@NP	cellular phospholipids	3727
@NP	23 -RSB-	3751
@NP	Prostaglandin or leukotriene	3756
@NP	tissue injury or inflammation -LSB- 24 -RSB-	3817
@NP	tissue injury or inflammation	3817
@NP	24 -RSB-	3848
@NP	Prostacyclin or its CNS analogs	3853
@NP	Prostacyclin	3853
@NP	its CNS analogs	3869
@NP	infarct volume	3914
@NP	ischemic rat brains	3932
@NP	-LSB- 25 , 26 -RSB-	3952
@NP	Administration of prostacyclin	3962
@NP	Administration	3962
@NP	prostacyclin	3980
@NP	the cortical lesion	4015
@NP	rats	4038
@NP	traumatic brain injury -LSB- 27 -RSB-	4048
@NP	traumatic brain injury	4048
@NP	27 -RSB-	4072
@NP	Lin et al. , -LSB- 25 -RSB- and our recent articles -LSB- 28 , 29 -RSB-	4077
@NP	Lin et al.	4077
@NP	Lin	4077
@NP	et al.	4081
@NP	25 -RSB- and our recent articles	4090
@NP	25 -RSB-	4090
@NP	our recent articles	4098
@NP	-LSB- 28 , 29	4118
@NP	beneficial effects of enhanced prostacyclin synthesis	4145
@NP	beneficial effects	4145
@NP	enhanced prostacyclin synthesis	4167
@NP	neuronal cultures	4202
@NP	Parkinsonian or ischemic brains	4234
@NP	Parkinsonian	4234
@NP	ischemic brains	4250
@NP	multiple sclerosis	4270
@NP	vessels-derived prostacyclin	4290
@NP	axonal remodeling of injured neuronal networks	4336
@NP	axonal remodeling	4336
@NP	injured neuronal networks	4357
@NP	CST fibers	4408
@NP	the repair process -LSB- 30 -RSB-	4436
@NP	the repair process	4436
@NP	30 -RSB-	4456
@NP	Prostacyclin	4461
@NP	remyelination and functional recovery	4488
@NP	mice	4529
@NP	spinal nerve demyelination -LSB- 31 -RSB-	4540
@NP	spinal nerve demyelination	4540
@NP	31 -RSB-	4568
@NP	These findings	4573
@NP	us	4597
@NP	the possibility	4608
@NP	prostacyclin	4629
@NP	spinal nerve regeneration	4657
@NP	We	4684
@NP	recombinant adenovirus vectors -LRB- Ad -RRB-	4704
@NP	recombinant adenovirus vectors	4704
@NP	Ad	4736
@NP	green fluorescence protein -LRB- GFP -RRB- , COX-1 , COX-2 or PGIS ,	4749
@NP	green fluorescence protein -LRB- GFP -RRB-	4749
@NP	green fluorescence protein	4749
@NP	GFP	4777
@NP	COX-1 , COX-2 or PGIS	4783
@NP	stable delivery of individual gene in infected cells	4818
@NP	stable delivery	4818
@NP	individual gene in infected cells	4837
@NP	individual gene	4837
@NP	infected cells	4856
@NP	combinational infection of AdCOX-1 and/or AdPGIS	4875
@NP	combinational infection	4875
@NP	AdCOX-1 and/or AdPGIS	4902
@NP	AdCOX-1	4902
@NP	AdPGIS	4917
@NP	we	4925
@NP	prostacyclin production in endothelial cells	4954
@NP	prostacyclin production	4954
@NP	endothelial cells	4981
@NP	-LSB- 32 , 33	4999
@NP	CNS cells	5014
@NP	-LSB- 28 , 29 -RSB-	5024
@NP	The present work	5034
@NP	the effects of augmented prostacyclin production in OEC	5066
@NP	the effects	5066
@NP	augmented prostacyclin production in OEC	5081
@NP	augmented prostacyclin production	5081
@NP	OEC	5118
@NP	adenoviral gene transfter on survival and regeneration of spinal axons	5125
@NP	adenoviral gene transfter	5125
@NP	survival and regeneration of spinal axons	5154
@NP	survival and regeneration	5154
@NP	spinal axons	5183
@NP	transplantation of AdPGIS-OEC	5202
@NP	transplantation	5202
@NP	AdPGIS-OEC	5221
@NP	thoracic T8-transected spinal cord	5235
@NP	Our goal	5271
@NP	an environment	5294
@NP	spinal nerve regrowth after spinal cord injury	5327
@NP	spinal nerve regrowth	5327
@NP	spinal cord injury	5355
@NP	Methods	5375
@NP	Reagents and antibodies Cultured medium	5383
@NP	Reagents and antibodies	5383
@NP	fetal bovine serum -LRB- FBS -RRB-	5424
@NP	fetal bovine serum	5424
@NP	FBS	5444
@NP	serumfree supplements and antibiotics	5450
@NP	Invitrogen -LRB- Carlsbad , CA , USA -RRB-	5508
@NP	Invitrogen	5508
@NP	Carlsbad	5520
@NP	CA	5530
@NP	USA	5534
@NP	Tissue culture plastics	5540
@NP	BD Bioscience -LRB- San Jose , CA , USA -RRB-	5574
@NP	BD Bioscience	5574
@NP	San Jose	5589
@NP	CA	5599
@NP	USA	5603
@NP	Millicell culture inserts	5609
@NP	Millipore -LRB- Watford , UK -RRB-	5645
@NP	Millipore	5645
@NP	Watford	5656
@NP	UK	5665
@NP	Primary antibodies used in the present study were	5670
@NP	Primary antibodies	5670
@NP	the present study were	5697
@NP	the present study	5697
@NP	rabbit or mouse antineuronal class	5721
@NP	III beta tubulin -LRB- clone TUJ-1 , Covance , NJ , USA -RRB-	5756
@NP	III beta tubulin	5756
@NP	clone TUJ-1	5774
@NP	Covance	5787
@NP	NJ , USA	5796
@NP	rabbit anti-GFAP or anti-S100 -LRB- Dako Cytomation , Ely , UK -RRB-	5806
@NP	rabbit anti-GFAP or anti-S100	5806
@NP	Dako Cytomation	5837
@NP	Ely	5854
@NP	UK	5859
@NP	mouse anti-low affinity nerve growth factor receptor -LRB- p75NGFR -RRB-	5864
@NP	mouse	5864
@NP	anti-low affinity nerve growth factor receptor -LRB- p75NGFR -RRB-	5870
@NP	anti-low affinity nerve growth factor receptor	5870
@NP	p75NGFR	5918
@NP	anti-P75	5927
@NP	rabbit antiserotonin -LRB- Chemicon -RRB-	5937
@NP	rabbit antiserotonin	5937
@NP	Chemicon	5959
@NP	goat anti-Î²-actin -LRB- Santa Cruz Biotechnology , Texas , USA -RRB-	5973
@NP	goat anti-Î²-actin	5973
@NP	Santa Cruz Biotechnology	5992
@NP	Texas	6018
@NP	USA	6025
@NP	all other chemicals	6056
@NP	Sigma-Aldrich Co.	6096
@NP	Cell culture and in vitro transduction The procedure to culture and purify OEC	6114
@NP	Cell culture and in vitro transduction The procedure to culture	6114
@NP	Cell culture and in vitro transduction	6114
@NP	Cell culture	6114
@NP	The procedure	6153
@NP	culture	6170
@NP	purify OEC	6182
@NP	the method described in Nash et al. , -LSB- 34 -RSB- with modification	6202
@NP	the method	6202
@NP	Nash et al. , -LSB- 34 -RSB-	6226
@NP	Nash et al.	6226
@NP	Nash	6226
@NP	et al.	6231
@NP	34 -RSB-	6240
@NP	modification	6249
@NP	the outer two layers of the adult Spraque-Dawley	6272
@NP	the outer two layers	6272
@NP	the adult Spraque-Dawley	6296
@NP	SD	6322
@NP	rat olfactory bulbs	6326
@NP	all meninges and blood vessels	6376
@NP	The tissues	6408
@NP	removal of trypsin	6467
@NP	removal	6467
@NP	trypsin	6478
@NP	the dissociated cells	6487
@NP	the	6487
@NP	cells	6503
@NP	uncoated dishes	6524
@NP	DMEM/F -12	6558
@NP	1:1 mixture	6569
@NP	Invitrogen	6582
@NP	10 % FBS for 48 h -LRB- at 37 Â°C and 5 % CO2 -RRB-	6612
@NP	10 % FBS	6612
@NP	48 h -LRB- at 37 Â°C and 5 % CO2 -RRB-	6624
@NP	48 h	6624
@NP	37 Â°C and 5 % CO2	6633
@NP	37 Â°C	6633
@NP	5 % CO2	6643
@NP	The suspended cells	6652
@NP	poly-D-lysine-coated dishes	6705
@NP	DMEM/F12	6751
@NP	10 % FBS and astrocyteconditioned medium -LRB- ACM -RRB-	6778
@NP	10 % FBS	6778
@NP	astrocyteconditioned medium -LRB- ACM -RRB-	6790
@NP	astrocyteconditioned medium	6790
@NP	ACM	6819
@NP	Astrocytes	6825
@NP	our recent articles	6866
@NP	-LSB- 29 , 35 -RSB-	6886
@NP	ACM	6896
@NP	the released medium of confluent astrocytes after conditioning for 2 days	6920
@NP	the released medium	6920
@NP	confluent astrocytes after conditioning for 2 days	6943
@NP	confluent astrocytes	6943
@NP	conditioning for 2 days	6970
@NP	conditioning	6970
@NP	2 days	6987
@NP	OEC cultures	6995
@NP	fresh medium and ACM	7027
@NP	every 2 days	7048
@NP	they	7067
@NP	confluence	7080
@NP	Confluent OEC	7092
@NP	immunohistochemistry	7127
@NP	co-culture studies -LRB- by seeding to insert well -RRB-	7155
@NP	co-culture studies	7155
@NP	study	7215
@NP	confluent OEC	7222
@NP	AdGFP or AdPGIS 2	7255
@NP	AdGFP	7255
@NP	AdPGIS 2	7264
@NP	3 days	7273
@NP	activity	7312
@NP	eicosanoids	7335
@NP	AA	7352
@NP	transplantation	7362
@NP	SCI rats	7381
@NP	Neuronal cultures and OGD treatment Mixed neuron-glial cell cultures	7391
@NP	Neuronal cultures	7391
@NP	OGD treatment Mixed neuron-glial cell cultures	7413
@NP	the cortical or spinal cord regions of Spraque-Dawley -LRB- SD -RRB- rat fetus	7479
@NP	cortical or spinal cord regions of Spraque-Dawley -LRB- SD -RRB-	7483
@NP	cortical or spinal cord regions	7483
@NP	Spraque-Dawley	7518
@NP	SD	7534
@NP	gestation of 15	7551
@NP	gestation	7551
@NP	15	7564
@NP	17 days	7567
@NP	Tsai et al. -LSB- 36 , 37	7591
@NP	Tsai et al.	7591
@NP	Tsai	7591
@NP	et al.	7596
@NP	-LSB- 36 , 37	7603
@NP	cells	7622
@NP	mixtures	7650
@NP	papain/protease/deoxyribonuclease I -LRB- 0.1 % : 0.1 % : 0.03 % -RRB-	7662
@NP	papain/protease/deoxyribonuclease I	7662
@NP	0.1 % : 0.1 % : 0.03 %	7699
@NP	0.1 %	7699
@NP	0.1 % : 0.03 %	7704
@NP	0.1 %	7704
@NP	0.03 %	7709
@NP	poly-D - lysine-coated dishes in DMEM supplemented with 10 % FBS	7732
@NP	poly-D	7732
@NP	lysine-coated dishes in DMEM supplemented with 10 % FBS	7740
@NP	lysine-coated dishes	7740
@NP	DMEM supplemented with 10 % FBS	7764
@NP	DMEM	7764
@NP	10 % FBS	7787
@NP	The cells	7796
@NP	37 Â°C in a water-saturated atmosphere of 5 % CO2/95 % air	7824
@NP	37 Â°C	7824
@NP	a water-saturated atmosphere of 5 % CO2/95 % air	7833
@NP	a water-saturated atmosphere	7833
@NP	5 % CO2/95 % air	7865
@NP	5 %	7865
@NP	CO2/95 %	7868
@NP	OGD treatment	7885
@NP	the culture media	7900
@NP	glucose-free DMEM	7937
@NP	an air-tight chamber	7971
@NP	0.5 %	8002
@NP	O2	8007
@NP	a gas mixture	8015
@NP	95 % N2/5 % CO2	8029
@NP	95 %	8029
@NP	N2/5 %	8033
@NP	3 h of OGD	8050
@NP	3 h	8050
@NP	OGD	8057
@NP	reperfusion	8062
@NP	the exposure medium	8101
@NP	normal growth medium	8126
@NP	Cultures	8148
@NP	none , OEC or AdPGIS-OEC	8184
@NP	0 h	8211
@NP	OGD reperfusion	8221
@NP	Two days later	8238
@NP	cultures	8254
@NP	propidium iodide -LRB- PI , 1 Î¼g/ml -RRB- for 4 h	8281
@NP	propidium iodide -LRB- PI , 1 Î¼g/ml -RRB-	8281
@NP	propidium iodide	8281
@NP	PI , 1 Î¼g/ml	8299
@NP	PI	8299
@NP	1 Î¼g/ml	8303
@NP	4 h	8316
@NP	fixation for immunohistochemistry	8327
@NP	fixation	8327
@NP	immunohistochemistry	8340
@NP	Images	8362
@NP	immunoreactive -LRB- IR -RRB- or PI	8372
@NP	immunoreactive -LRB- IR -RRB-	8372
@NP	PI	8395
@NP	+	8399
@NP	a fluorescent microscope	8428
@NP	a cooling digital imaging system	8467
@NP	BetaIII tubulin-IR neurite density and PI -LRB- + -RRB- or	8501
@NP	BetaIII tubulin-IR neurite density	8501
@NP	PI -LRB- + -RRB- or	8540
@NP	PI -LRB- + -RRB-	8540
@NP	PI	8540
@NP	+	8544
@NP	+	8555
@NP	cell	8558
@NP	numbers -LRB- obtained using a 20x object lens -RRB-	8563
@NP	numbers	8563
@NP	a 20x object lens	8587
@NP	Image-Pro plus software -LRB- NIH systems , Bethesda , MD , USA -RRB-	8626
@NP	Image-Pro	8626
@NP	software -LRB- NIH systems , Bethesda , MD , USA -RRB-	8641
@NP	software	8641
@NP	NIH systems	8651
@NP	Bethesda	8664
@NP	MD , USA	8674
@NP	Recombinant adenovirus -LRB- Ad -RRB- Replication-defective first generation	8684
@NP	Recombinant adenovirus	8684
@NP	Ad	8708
@NP	Replication-defective first generation	8712
@NP	E1-deleted adenoviral vectors	8751
@NP	The recombinant adenoviruses	8792
@NP	phosphoglycerate kinase -LRB- PGK -RRB- as a driving promoter	8826
@NP	phosphoglycerate kinase -LRB- PGK -RRB-	8826
@NP	phosphoglycerate kinase	8826
@NP	PGK	8851
@NP	a driving promoter	8859
@NP	AdPGK -LRB- containing the promoter only without encoding gene -RRB-	8879
@NP	AdPGK	8879
@NP	the promoter	8897
@NP	gene	8932
@NP	a vector control	8950
@NP	AdGFP	8968
@NP	the infection conditions	9002
@NP	Large-scale production	9028
@NP	high titer	9054
@NP	âˆ¼ 1010 pfu/mL	9066
@NP	âˆ¼	9066
@NP	1010 pfu/mL	9067
@NP	adenovirus encoding none , GFP , or PGIS	9083
@NP	adenovirus	9083
@NP	none , GFP , or PGIS	9103
@NP	previous articles	9152
@NP	-LSB- 28 , 29 -RSB-	9170
@NP	AdGFP	9180
@NP	OEC culture	9199
@NP	a multiplicity of injection -LRB- MOI -RRB- of 50	9216
@NP	a multiplicity	9216
@NP	injection -LRB- MOI -RRB- of 50	9234
@NP	injection -LRB- MOI -RRB-	9234
@NP	injection	9234
@NP	MOI	9245
@NP	50	9253
@NP	transduction of virtually all cultured cells	9270
@NP	transduction	9270
@NP	virtually all cultured cells	9286
@NP	virtually all	9286
@NP	cells	9309
@NP	50 MOI each of recombinant Ads	9322
@NP	50 MOI each	9322
@NP	50 MOI	9322
@NP	each	9329
@NP	recombinant Ads	9337
@NP	infection	9366
@NP	OEC ex vivo	9388
@NP	OEC	9401
@NP	SCI rats at 2	9421
@NP	SCI rats	9421
@NP	2	9433
@NP	3 days	9435
@NP	AdPGK , AdGFP or AdPGIS	9468
@NP	ex vivo	9491
@NP	Extraction and analysis	9500
@NP	arachidonic acid -LRB- AA -RRB- metabolites in cultured cells	9527
@NP	arachidonic acid -LRB- AA -RRB- metabolites	9527
@NP	AA	9545
@NP	cultured cells	9564
@NP	OEC	9588
@NP	recombinant adenoviral infection	9598
@NP	2	9635
@NP	3 days	9639
@NP	eicosanoids	9692
@NP	AA	9709
@NP	the methods described in our recent articles -LSB- 28 , 29 -RSB-	9725
@NP	the methods	9725
@NP	our recent articles	9750
@NP	-LSB- 28 , 29 -RSB-	9770
@NP	confluent cells	9789
@NP	10 Î¼M -LSB- 1-14C -RSB- AA	9856
@NP	10 Î¼M	9856
@NP	1-14C -RSB- AA	9863
@NP	37 Â°C for 10 min	9876
@NP	37 Â°C	9876
@NP	10 min	9886
@NP	The	9894
@NP	cells	9907
@NP	western blot analysis	9932
@NP	the media , containing released eicosanoids ,	9958
@NP	the media	9958
@NP	eicosanoids	9989
@NP	analysis of -LSB- 1-14C	10017
@NP	analysis	10017
@NP	-LSB- 1-14C	10029
@NP	AA metabolites	10045
@NP	The extracted -LSB- 1-14C	10061
@NP	AA metabolites	10091
@NP	reverse phase HPLC	10123
@NP	a solvent delivery system -LRB- Waters model 2690 -RRB-	10143
@NP	a solvent delivery system	10143
@NP	Waters model 2690	10170
@NP	an on-line radioisotopic detector -LRB- Packard 150-TP -RRB-	10203
@NP	an on-line radioisotopic detector	10203
@NP	Packard 150-TP	10238
@NP	methods described previously -LSB- 29 , 32 -RSB-	10263
@NP	methods	10263
@NP	-LSB- 29 , 32 -RSB-	10292
@NP	The -LSB- 1-14C -RSB- eicosanoids	10302
@NP	The -LSB- 1-14C	10302
@NP	eicosanoids	10314
@NP	their retention times	10345
@NP	the authentic radioisotopic standands	10372
@NP	Animal surgery and treatment Adult SD rats	10411
@NP	NYU Animal Breeding and Research Center in Taiwan	10469
@NP	NYU Animal Breeding and Research Center	10469
@NP	Taiwan	10512
@NP	the present study	10534
@NP	The surgical procedures	10553
@NP	spinal cord transection and post-operative animal care	10581
@NP	spinal cord transection	10581
@NP	post-operative animal care	10609
@NP	the Institutional Animal Care and Use Committee -LRB- IACUC -RRB-	10670
@NP	the Institutional Animal Care and Use Committee	10670
@NP	IACUC	10719
@NP	Taipei Veterans General Hospital and Reg	10729
@NP	Taipei Veterans General Hospital	10729
@NP	Reg	10766
@NP	No 2014 -- 002 .	10771
@NP	No 2014	10771
@NP	002	10779
@NP	All efforts	10784
@NP	animal suffering	10819
@NP	surgery	10857
@NP	the numbers of animals that were sacrificed	10879
@NP	the numbers	10879
@NP	animals that were sacrificed	10894
@NP	animals	10894
@NP	Spinal cord transection surgery	10924
@NP	the previously described protocols -LSB- 36 , 38 , 39 -RSB-	10983
@NP	the previously	10983
@NP	protocols	11008
@NP	-LSB- 36 , 38 , 39 -RSB-	11018
@NP	rats	11041
@NP	1 -- 2 % isoflurane -LRB- Baxter , Guayama , PR , USA -RRB-	11069
@NP	1	11069
@NP	2 % isoflurane -LRB- Baxter , Guayama , PR , USA -RRB-	11073
@NP	2 % isoflurane	11073
@NP	Baxter	11088
@NP	Guayama	11096
@NP	PR , USA	11105
@NP	The body temperature	11115
@NP	surgery	11158
@NP	37 Â± 0.5 Â°C	11169
@NP	37 Â±	11169
@NP	0.5 Â°C	11174
@NP	a heating pad servo-controlled by a rectal probe	11186
@NP	a heating pad	11186
@NP	a rectal probe	11220
@NP	A laminectomy	11236
@NP	the thoracic vertebral level 8 -LRB- T8 -RRB-	11262
@NP	the thoracic vertebral level	11262
@NP	8 -LRB- T8 -RRB-	11291
@NP	The meningeal membranes	11299
@NP	the dura mater	11347
@NP	The spinal cord	11363
@NP	a 5 mm segment of spinal cord encompassing T8 being removed	11410
@NP	a 5 mm segment	11410
@NP	spinal cord encompassing T8 being removed	11428
@NP	spinal cord encompassing T8	11428
@NP	The rostral and caudal stumps	11471
@NP	The rostral	11471
@NP	caudal stumps	11487
@NP	removal of the spinal cord segment	11519
@NP	removal	11519
@NP	the spinal cord segment	11530
@NP	complete discontinuity	11564
@NP	cells	11601
@NP	a total of 5 Ã— 105 OEC in fibrin solution ,	11608
@NP	a total	11608
@NP	5 Ã—	11619
@NP	105 OEC in fibrin solution	11622
@NP	105 OEC	11622
@NP	fibrin solution	11633
@NP	the transected cavity	11666
@NP	the	11666
@NP	cavity	11681
@NP	The muscle layers and the skins	11689
@NP	The muscle layers	11689
@NP	the skins	11711
@NP	Bladder evacuation	11745
@NP	experimental rats	11779
@NP	Behavior test for hindlimb performance	11810
@NP	Behavior test	11810
@NP	hindlimb performance	11828
@NP	transplantation	11879
@NP	3 months postgrafting	11899
@NP	3 months	11899
@NP	experimental rats	11922
@NP	anterograde tracing	11959
@NP	anterograde	11959
@NP	immunohistochemical staining	11986
@NP	Histological procedures	12016
@NP	Anterograde	12040
@NP	WGA-horseradish peroxidase	12073
@NP	HRP	12101
@NP	experimental rats at 12	12123
@NP	experimental rats	12123
@NP	12	12144
@NP	week	12147
@NP	surgery and transplantation	12158
@NP	WGA-HRP	12187
@NP	the hindlimb area	12229
@NP	the sensory motor cortex -LRB- 10 sites , bilaterally , 0.3 Î¼l/site -RRB-	12250
@NP	the sensory motor cortex	12250
@NP	10 sites , bilaterally , 0.3 Î¼l/site	12276
@NP	10 sites , bilaterally	12276
@NP	10 sites	12276
@NP	0.3 Î¼l/site	12299
@NP	experimental rats	12315
@NP	anesthesia	12339
@NP	All injections	12351
@NP	a 3 min period	12386
@NP	the injection needle	12406
@NP	place for an additional 3 min	12439
@NP	place	12439
@NP	an additional 3 min	12449
@NP	leakage	12481
@NP	needle withdrawal	12492
@NP	the injection	12517
@NP	the muscles and skin	12532
@NP	the muscles	12532
@NP	skin	12548
@NP	layers	12568
@NP	Rats	12576
@NP	2 days	12603
@NP	tracer identification in spinal cords	12632
@NP	tracer identification	12632
@NP	spinal cords	12657
@NP	longitudinal sections -LRB- 14 Î¼m -RRB-	12680
@NP	longitudinal sections	12680
@NP	14 Î¼m	12703
@NP	thoracic spinal cord -LRB- T7 - T9 -RRB-	12713
@NP	thoracic spinal cord	12713
@NP	T7 - T9	12735
@NP	T7	12735
@NP	T9	12739
@NP	tetramethylbenzidine -LRB- TMB -RRB- for HRP histochemistry	12763
@NP	tetramethylbenzidine -LRB- TMB -RRB-	12763
@NP	tetramethylbenzidine	12763
@NP	TMB	12785
@NP	HRP histochemistry	12794
@NP	TMB substrate kit -LRB- SK-4400 , Vector -RRB-	12826
@NP	TMB substrate kit	12826
@NP	SK-4400	12845
@NP	Vector	12854
@NP	immunohistochemical analysis	12867
@NP	rats	12897
@NP	phosphate-buffered 4 % paraformaldehyde at 3 or 12 weeks	12954
@NP	phosphate-buffered 4 % paraformaldehyde	12954
@NP	at 3 or 12 weeks	12993
@NP	transplanation	13016
@NP	The spinal segments	13032
@NP	4 % paraformaldehyde	13070
@NP	PBS	13127
@NP	30 % -LRB- w/v -RRB-	13142
@NP	30 %	13142
@NP	w/v	13147
@NP	sucrose for 3 days	13152
@NP	sucrose	13152
@NP	3 days	13164
@NP	The tissues	13172
@NP	Tissue TekOCT -LRB- Sakura Fine Technical , Tokyo , Japan -RRB-	13213
@NP	Tissue TekOCT	13213
@NP	Sakura Fine Technical	13228
@NP	Tokyo	13251
@NP	Japan	13258
@NP	20 Î¼m thickness with a cryostat	13293
@NP	20 Î¼m thickness	13293
@NP	a cryostat	13314
@NP	Immunohistochemical analysis	13326
@NP	Frozen spinal sections	13355
@NP	immunohistochemistry	13397
@NP	method described in our recent articles -LSB- 35 , 39 -RSB-	13427
@NP	method	13427
@NP	our recent articles	13447
@NP	-LSB- 35 , 39 -RSB-	13467
@NP	The tissue sections	13477
@NP	primary antibodies	13517
@NP	respective 2nd antibodies for histological evaluation	13549
@NP	respective 2nd antibodies	13549
@NP	histological evaluation	13579
@NP	double immunostaining	13952
@NP	the secondary antibodies used	13975
@NP	the secondary antibodies	13975
@NP	Alex 488 fluorophore	14010
@NP	donkey anti-rabbit antibody	14031
@NP	1:200	14060
@NP	Molecular Probes , Eugene , OR , USA	14067
@NP	Molecular Probes	14067
@NP	Eugene	14085
@NP	OR	14093
@NP	USA	14097
@NP	Cy3-conjugated donkey	14106
@NP	anti-mouse antibody	14128
@NP	1:200 ; Jackson ImmunoResearch Laboratories	14149
@NP	1:200	14149
@NP	Jackson ImmunoResearch Laboratories	14156
@NP	West Grove , PA	14193
@NP	West Grove	14193
@NP	PA	14205
@NP	Primary antibody omission controls	14210
@NP	all immunostaining protocols	14264
@NP	nonspecific binding	14308
@NP	Fluorescent visualization and photography	14329
@NP	Fluorescent visualization	14329
@NP	photography	14359
@NP	a Zeiss Axioscope microscope	14389
@NP	appropriate filter sets -LRB- Zeiss , Oberkochen , Germany -RRB-	14423
@NP	appropriate filter sets	14423
@NP	Zeiss	14448
@NP	Oberkochen	14455
@NP	Germany	14467
@NP	Behavioral assessment Hindlimb performance	14477
@NP	the open field locomotor test	14540
@NP	Basso et al. -LSB-	14593
@NP	40 -RSB-	14607
@NP	our recent articles	14627
@NP	-LSB- 36 , 39	14647
@NP	Two observers , unaware of the experimental procedures ,	14657
@NP	Two observers	14657
@NP	the experimental procedures	14683
@NP	the test	14722
@NP	the Basso Beattie Bresnahan -LRB- BBB -RRB- open field	14753
@NP	Basso Beattie Bresnahan -LRB- BBB -RRB-	14757
@NP	Basso Beattie Bresnahan	14757
@NP	BBB	14782
@NP	locomotor test	14798
@NP	Behavior Score -LRB- CBS -RRB- scales	14826
@NP	The BBB scale	14855
@NP	0 -LRB- no hindlimb movement -RRB-	14881
@NP	0	14881
@NP	no hindlimb movement	14884
@NP	21 -LRB- normal movement-coordinated gait -RRB- -LSB- 40 -RSB-	14909
@NP	21 -LRB- normal movement-coordinated gait -RRB-	14909
@NP	21	14909
@NP	normal movement-coordinated gait	14913
@NP	40 -RSB-	14948
@NP	Western blot analysis After experimental periods , cultured cells	14953
@NP	Western blot analysis	14953
@NP	experimental periods , cultured cells	14981
@NP	experimental periods	14981
@NP	cells	15012
@NP	PBS	15041
@NP	lysis buffer	15064
@NP	40 mM Tris buffer -LRB- pH 7.5 -RRB-	15088
@NP	40 mM	15088
@NP	Tris buffer -LRB- pH 7.5 -RRB-	15094
@NP	Tris buffer	15094
@NP	pH 7.5	15107
@NP	8 M urea	15116
@NP	4 % CHAPS	15126
@NP	1 mM PMSF , 1 mM Na3VO4 , 1 mM dithiothreitol	15136
@NP	1 mM PMSF	15136
@NP	1 mM Na3VO4	15147
@NP	1 mM dithiothreitol	15160
@NP	a protease inhibitor kit -LRB- BM , Germany -RRB-	15185
@NP	a protease inhibitor kit	15185
@NP	BM	15211
@NP	Germany	15215
@NP	Protein	15225
@NP	a Biorad protein assay reagent	15251
@NP	Aliquots of proteins -LRB- 5 Î¼g -RRB- of the cell lysates	15283
@NP	Aliquots	15283
@NP	proteins -LRB- 5 Î¼g -RRB- of the cell lysates	15295
@NP	proteins -LRB- 5 Î¼g -RRB-	15295
@NP	proteins	15295
@NP	5 Î¼g	15305
@NP	the cell lysates	15314
@NP	western blot	15348
@NP	SDS-PAGE -LRB- 8 % or 12 % gel -RRB- , as previously described -LSB- 35 , 41	15368
@NP	SDS-PAGE -LRB- 8 % or 12 % gel -RRB-	15368
@NP	SDS-PAGE	15368
@NP	8 % or 12 % gel	15378
@NP	8 %	15378
@NP	12 % gel	15384
@NP	-LSB- 35 , 41	15418
@NP	electrophoresis	15434
@NP	gels	15451
@NP	PVDF membranes -LRB- Millipore Corp. , USA -RRB-	15476
@NP	PVDF membranes	15476
@NP	Millipore Corp.	15492
@NP	USA	15509
@NP	overnight at 4 Â°C	15528
@NP	overnight	15528
@NP	4 Â°C	15541
@NP	antibodies	15551
@NP	PGIS -LRB- rabbit , dilution 1/3000 -RRB-	15570
@NP	PGIS	15570
@NP	rabbit	15576
@NP	dilution 1/3000	15584
@NP	COX-1	15602
@NP	COX-2 -LRB- rabbit , dilution 1/5000 , Cayman -RRB-	15609
@NP	COX-2	15609
@NP	rabbit	15616
@NP	dilution 1/5000	15624
@NP	Cayman	15641
@NP	Î²-actin -LRB- 1:5000 ; Santa Cruz Biotech , USA -RRB-	15652
@NP	Î²-actin	15652
@NP	1:5000 ; Santa Cruz Biotech , USA	15661
@NP	1:5000	15661
@NP	Santa Cruz Biotech , USA	15669
@NP	a HRP-conjugated secondary antibody -LRB- dilution 1/2000 , Jackson Lab -RRB-	15706
@NP	a HRP-conjugated secondary antibody	15706
@NP	dilution 1/2000	15743
@NP	Jackson Lab	15760
@NP	1 h at room temperature	15777
@NP	1 h	15777
@NP	room temperature	15784
@NP	Immunoreactivity	15802
@NP	enhanced chemiluminescent detection -LRB- Perkin Elmer Co , USA -RRB-	15837
@NP	enhanced chemiluminescent detection	15837
@NP	Perkin Elmer Co	15874
@NP	USA	15891
@NP	Statistical analysis Experimental data	15897
@NP	the mean of independent values	15954
@NP	the mean	15954
@NP	independent values	15966
@NP	s.e.m.	15987
@NP	one-way analysis of variance -LRB- ANOVA -RRB- followed by LSD test	16018
@NP	one-way analysis	16018
@NP	variance -LRB- ANOVA -RRB- followed by LSD test	16038
@NP	variance	16038
@NP	ANOVA	16048
@NP	LSD test	16067
@NP	Values of P < 0.05	16077
@NP	Values	16077
@NP	P < 0.05	16087
@NP	P	16087
@NP	< 0.05	16089
@NP	<	16089
@NP	0.05	16091
@NP	statistical significance	16120
@NP	Results	16147
@NP	Table 1	16155
@NP	Results of animal behavior	16163
@NP	Results	16163
@NP	animal behavior	16174
@NP	WGA-HRP and 5-TH immunoreactivity at 12 weeks after injury and treatment	16211
@NP	WGA-HRP and 5-TH immunoreactivity	16211
@NP	12 weeks after injury and treatment	16248
@NP	12 weeks	16248
@NP	injury and treatment	16263
@NP	A few 5HT	16284
@NP	+	16295
@NP	the distal stump	16319
@NP	1 mm distal to the transected gap	16344
@NP	1 mm	16344
@NP	the transected gap	16359
@NP	one Tx + OEC Tp and three Tx + AdPGIS-OEC Tp rats	16382
@NP	one Tx + OEC Tp	16382
@NP	one Tx	16382
@NP	OEC Tp	16391
@NP	three Tx + AdPGIS-OEC Tp rats	16402
@NP	three Tx	16402
@NP	AdPGIS-OEC Tp rats	16413
@NP	motor cortex in experimental rats	16471
@NP	motor cortex	16471
@NP	experimental rats	16487
@NP	WGA	16506
@NP	+	16511
@NP	the thoracic level 12 in two Tx + AdPGIS-OEC Tp rats	16535
@NP	the thoracic level 12	16535
@NP	two Tx + AdPGIS-OEC Tp rats	16560
@NP	two Tx	16560
@NP	AdPGIS-OEC Tp rats	16569
@NP	Nuclei	17092
@NP	Hoechst 33258 -LRB- blue -RRB-	17123
@NP	Hoechst 33258	17123
@NP	blue	17138
@NP	Bar	17145
@NP	50 Î¼m	17151
@NP	Data	17158
@NP	average Â± SD	17180
@NP	the results	17207
@NP	two independent experiments	17222
@NP	triplicate -LRB- n = 6 per experimental conditions -RRB-	17263
@NP	triplicate	17263
@NP	n = 6 per experimental conditions	17275
@NP	n = 6	17275
@NP	n	17275
@NP	6	17279
@NP	experimental conditions	17285
@NP	that OEC	17316
@NP	Ad-GFP infection Fig. 2 The enzyme activity	17350
@NP	Ad-GFP infection Fig. 2	17350
@NP	Ad-GFP infection Fig.	17350
@NP	2	17373
@NP	The enzyme activity	17375
@NP	respective protein expression of eicosanoid biosynthesis	17399
@NP	respective protein expression	17399
@NP	eicosanoid biosynthesis	17432
@NP	OEC	17468
@NP	a & b	17473
@NP	a	17473
@NP	b	17477
@NP	HPLC analysis	17480
@NP	14C-labelled eicosanoids	17497
@NP	Control and AdPGIS-transduced OEC cultures	17535
@NP	response to -LSB- 1-14C -RSB- arachidonic acid -LRB- AA -RRB-	17596
@NP	response	17596
@NP	-LSB- 1-14C -RSB- arachidonic acid -LRB- AA -RRB-	17608
@NP	-LSB- 1-14C -RSB- arachidonic acid	17608
@NP	-LSB- 1-14C -RSB-	17608
@NP	AA	17634
@NP	6-keto-PGF1Î± , the product of PGI2 hydrolysis	17652
@NP	6-keto-PGF1Î±	17652
@NP	the product of PGI2 hydrolysis	17666
@NP	the product	17666
@NP	PGI2 hydrolysis	17681
@NP	Each prostanoid peak	17698
@NP	coelution	17735
@NP	an authentic radiolabelled prostanoid	17750
@NP	c : Western blot analysis of protein levels of PGIS , COX-1 and COX-2	17789
@NP	c	17789
@NP	Western blot analysis of protein levels of PGIS , COX-1 and COX-2	17792
@NP	Western blot analysis	17792
@NP	protein levels of PGIS , COX-1 and COX-2	17817
@NP	protein levels	17817
@NP	PGIS , COX-1 and COX-2	17835
@NP	OEC receiving AdPGK or AdPGIS infection	17869
@NP	OEC	17869
@NP	AdPGK or AdPGIS infection	17883
@NP	Measurement	17910
@NP	eicosanoid biosynthesis and biosynthetic enzyme expression in cultures	17925
@NP	eicosanoid biosynthesis and biosynthetic enzyme expression	17925
@NP	cultures	17987
@NP	3 days	18013
@NP	Ads transduction	18026
@NP	Confluent OEC cultures	18044
@NP	-LSB- 1-14C -RSB- AA for 10 min	18084
@NP	-LSB- 1-14C -RSB- AA	18084
@NP	-LSB- 1-14C -RSB-	18084
@NP	10 min	18099
@NP	The released -LSB- 1-14C -RSB- eicosanoids in the released medium of OEC	18107
@NP	The released -LSB- 1-14C -RSB- eicosanoids	18107
@NP	1-14C -RSB-	18121
@NP	the released medium of OEC	18143
@NP	the released medium	18143
@NP	OEC	18166
@NP	HPLC with a radiochemical flowthrough detector	18213
@NP	HPLC	18213
@NP	a radiochemical flowthrough detector	18223
@NP	that OEC	18266
@NP	COX-1 and COX-2 but not PGIS	18300
@NP	COX-1 and COX-2	18300
@NP	PGIS	18324
@NP	Bar	18882
@NP	100 Î¼m	18888
@NP	P <	18901
@NP	P	18901
@NP	<	18903
@NP	0.01,0.05 , compared to neuron-glial cultures	18905
@NP	0.01,0.05	18905
@NP	neuron-glial cultures	18928
@NP	One-way analysis of variance + Bonferroni post test .	18951
@NP	One-way analysis	18951
@NP	variance + Bonferroni post test	18971
@NP	variance	18971
@NP	Data	19004
@NP	mean Â± SEM	19027
@NP	the results of three	19049
@NP	the results	19049
@NP	three	19064
@NP	independent experiments	19070
@NP	n = 8-10 per experimental conditions	19095
@NP	n = 8-10	19095
@NP	n	19095
@NP	8-10	19098
@NP	experimental conditions	19107
@NP	Fig.	19133
@NP	4 PGIS-overexpressing OEC cocultures	19138
@NP	neuronal connection	19184
@NP	microglial number in spinal cord	19216
@NP	microglial number	19216
@NP	spinal cord	19237
@NP	neuron-glial cultures	19249
@NP	a & d	19273
@NP	a	19273
@NP	d	19277
@NP	neuron-glial cultures only , -LRB- b & e -RRB-	19281
@NP	neuron-glial	19281
@NP	cultures only , -LRB- b & e -RRB-	19294
@NP	cultures only	19294
@NP	cultures	19294
@NP	b & e	19310
@NP	neuron-glial cultures	19318
@NP	Con-OEC , -LRB- c & f -RRB-	19356
@NP	Con-OEC	19356
@NP	c & f	19366
@NP	c	19366
@NP	f	19370
@NP	neuron-glial cultures cocultured with PGISOEC , -LRB- g & h -RRB-	19374
@NP	neuron-glial cultures	19374
@NP	PGISOEC , -LRB- g & h -RRB-	19412
@NP	PGISOEC	19412
@NP	g & h	19422
@NP	g	19422
@NP	h	19426
@NP	quantitative bar charts for tubulin immunoreactivity and ED1	19430
@NP	quantitative bar charts	19430
@NP	tubulin immunoreactivity and ED1	19458
@NP	cell numbers , respectively	19495
@NP	cell numbers	19495
@NP	A-C	19523
@NP	immunoreactive cells	19539
@NP	D-F	19564
@NP	-LRB- + -RRB- microglial cells	19576
@NP	+	19577
@NP	Bar	19598
@NP	100 Î¼m	19604
@NP	P <	19617
@NP	P	19617
@NP	<	19619
@NP	0.01,0.05	19621
@NP	neuron-glial cultures	19644
@NP	one-way analysis of variance + Bonferroni post test	19670
@NP	one-way analysis	19670
@NP	variance + Bonferroni post test	19690
@NP	variance	19690
@NP	Data	19723
@NP	mean Â± SEM	19746
@NP	the results	19768
@NP	two independent experiments performed in duplicate-triplicate Fig.	19783
@NP	two independent experiments	19783
@NP	duplicate-triplicate Fig.	19824
@NP	5 Spinal cord transection injury and transplantation of OEC a	19851
@NP	5 Spinal cord transection	19851
@NP	injury and transplantation of OEC a	19877
@NP	injury and transplantation	19877
@NP	OEC a	19907
@NP	Scheme	19914
@NP	segments of thoracic spinal cord -LRB- T7 ~ T9 ; R : rostral ; C : caudal -RRB-	19929
@NP	segments	19929
@NP	thoracic spinal cord -LRB- T7 ~ T9 ; R : rostral ; C : caudal -RRB-	19941
@NP	thoracic spinal cord	19941
@NP	T7 ~ T9	19963
@NP	T7	19963
@NP	~ T9	19966
@NP	R : rostral ; C : caudal	19972
@NP	R	19972
@NP	rostral ; C	19975
@NP	rostral	19975
@NP	C	19984
@NP	caudal	19987
@NP	The location of GFP expressing OEC	19996
@NP	The location	19996
@NP	GFP expressing OEC	20012
@NP	GFP	20012
@NP	OEC	20027
@NP	EDF	20045
@NP	Complete transection injury -LRB- with a 5 mm gap -RRB- in thoracic spinal cord	20053
@NP	Complete transection injury -LRB- with a 5 mm gap -RRB-	20053
@NP	Complete transection injury	20053
@NP	a 5 mm gap	20087
@NP	thoracic spinal cord	20102
@NP	c : Transplantation of fibrin glue-mixed OEC	20124
@NP	c	20124
@NP	Transplantation of fibrin glue-mixed OEC	20127
@NP	Transplantation	20127
@NP	fibrin glue-mixed OEC	20146
@NP	the transection cavity	20171
@NP	d-f GFP-expressing OEC in the transection cavity of spinal cord	20195
@NP	d-f GFP-expressing OEC	20195
@NP	the transection cavity of spinal cord	20221
@NP	the transection cavity	20221
@NP	spinal cord	20247
@NP	1 week posttransplantation	20262
@NP	d Higher magnification of GFP -LRB- + -RRB- OEC .	20290
@NP	d	20290
@NP	Higher magnification of GFP -LRB- + -RRB- OEC	20292
@NP	Higher magnification of GFP -LRB- + -RRB-	20292
@NP	Higher magnification	20292
@NP	GFP	20316
@NP	+	20321
@NP	OEC	20324
@NP	Bar	20329
@NP	150 Î¼m in d , 50 Î¼m in e	20335
@NP	150 Î¼m	20335
@NP	d , 50 Î¼m in e	20345
@NP	d	20345
@NP	50 Î¼m in e	20348
@NP	50 Î¼m	20348
@NP	f. g-i GFP-expressing OEC in the spinal stumps of 3 week SCI rats at 4	20359
@NP	f. g-i	20359
@NP	GFP-expressing OEC in the spinal stumps of 3 week SCI rats at 4	20366
@NP	GFP-expressing OEC	20366
@NP	the spinal stumps of 3 week SCI rats at 4	20388
@NP	the spinal stumps	20388
@NP	3 week SCI rats at 4	20409
@NP	3 week SCI rats	20409
@NP	4	20428
@NP	5 mm rostral or caudal	20430
@NP	5 mm rostral	20430
@NP	caudal	20446
@NP	the lesion epicenter	20456
@NP	Bar	20478
@NP	50 Î¼m	20484
@NP	Adult OEC	20491
@NP	GFP	20523
@NP	adenovirus - mediated gene transfer before transplantation	20530
@NP	adenovirus	20530
@NP	gene transfer	20551
@NP	transplantation	20572
@NP	one week post-transplanation	20598
@NP	GFP	20628
@NP	+	20633
@NP	the transected cavity -LRB- in d -RRB-	20654
@NP	the transected cavity	20654
@NP	d	20680
@NP	regions close to both spinal stumps -LRB- marked with star in e & f -RRB-	20690
@NP	regions close to both spinal stumps	20690
@NP	regions	20690
@NP	both spinal stumps	20707
@NP	star in e	20739
@NP	star	20739
@NP	& f	20749
@NP	3 weeks postgraft	20758
@NP	+	20782
@NP	both stumps	20801
@NP	4	20816
@NP	5 mm	20818
@NP	rotstral or caudal to the lesion epicenter	20823
@NP	rotstral or caudal	20823
@NP	the lesion epicenter	20845
@NP	AdGFP-OEC	20875
@NP	GFP persistently in the host spinal cord for at least 3 weeks Fig.	20911
@NP	the host spinal cord for at least 3 weeks	20931
@NP	the host spinal cord	20931
@NP	at least 3 weeks	20956
@NP	6 Iba1-immunoreative microglial cells	20979
@NP	the spinal cords of SCI rats at 3 weeks postinjury	21020
@NP	the spinal cords	21020
@NP	SCI rats at 3 weeks postinjury	21040
@NP	SCI rats	21040
@NP	3 weeks postinjury	21052
@NP	a & b : rostral stump ; c & d :	21072
@NP	a & b : rostral stump	21072
@NP	& b : rostral	21074
@NP	& b	21074
@NP	c & d	21094
@NP	c	21094
@NP	d	21098
@NP	gap	21112
@NP	&	21119
@NP	caudal stumps	21124
@NP	a , c ,	21139
@NP	a	21139
@NP	c	21142
@NP	GFP-OEC-grafted spinal cords ; b , d , f : PGIS-OEC-grafted spinal cords	21148
@NP	GFP-OEC-grafted spinal cords	21148
@NP	b	21178
@NP	d , f : PGIS-OEC-grafted spinal cords	21181
@NP	d , f	21181
@NP	d	21181
@NP	f	21184
@NP	PGIS-OEC-grafted spinal cords	21187
@NP	Green label	21218
@NP	Iba1 positive microglia	21236
@NP	g	21261
@NP	The histograms	21264
@NP	the percentage	21284
@NP	Iba1-positive microglia	21302
@NP	the spinal cords	21329
@NP	SCI rats	21349
@NP	SCI rats	21408
@NP	OEC or AdPGIS-OEC transplant	21427
@NP	transection spinal cord injury	21462
@NP	a & b	21494
@NP	a	21494
@NP	b	21498
@NP	BBB scores	21501
@NP	line chart and scatter plot , respectively , of SCI rats	21526
@NP	line chart and scatter plot , respectively ,	21526
@NP	line chart and scatter plot	21526
@NP	SCI rats	21572
@NP	none , OEC graft or AdPGIS-OEC graft , -LRB- c -RRB-	21591
@NP	none , OEC graft or AdPGIS-OEC graft ,	21591
@NP	none	21591
@NP	OEC graft or AdPGIS-OEC graft	21597
@NP	c	21629
@NP	CBS score of SCI rats receiving none , OEC graft or AdPGIS-OEC graft	21633
@NP	CBS score	21633
@NP	SCI rats	21646
@NP	none , OEC graft or AdPGIS-OEC graft	21665
@NP	none	21665
@NP	OEC graft	21671
@NP	AdPGIS-OEC graft	21684
@NP	OEC transplant	21702
@NP	functional recovery	21725
@NP	a complete transection	21751
@NP	spinal cord	21777
@NP	Scatter plot	21790
@NP	the BBB score for the control -LRB- TX -RRB- and transplant animals at 12 weeks	21811
@NP	the BBB score for the control -LRB- TX -RRB-	21811
@NP	the BBB score	21811
@NP	the control -LRB- TX -RRB-	21829
@NP	the control	21829
@NP	TX	21842
@NP	transplant animals at 12 weeks	21850
@NP	transplant animals	21850
@NP	12 weeks	21872
@NP	the transplantation of OEC	21887
@NP	the transplantation	21887
@NP	OEC	21910
@NP	a , P	21915
@NP	a	21915
@NP	P	21918
@NP	< 0.05 Tx	21920
@NP	<	21920
@NP	0.05 Tx	21922
@NP	OEC Tp versus Tx only	21932
@NP	OEC Tp	21932
@NP	Tx only	21946
@NP	b , P < 0.05 Tx + AdPGIS-OEC Tp versus Tx only	21954
@NP	b	21954
@NP	P < 0.05 Tx + AdPGIS-OEC Tp versus Tx only	21957
@NP	P < 0.05 Tx	21957
@NP	P <	21957
@NP	P	21957
@NP	0.05 Tx	21961
@NP	AdPGIS-OEC Tp versus Tx only	21971
@NP	AdPGIS-OEC Tp	21971
@NP	Tx only	21992
@NP	c , P < 0.05 Tx + AdPGIS-OEC Tp versus Tx + OEC Tp ã€‚	22001
@NP	c	22001
@NP	P < 0.05 Tx + AdPGIS-OEC Tp versus Tx + OEC Tp ã€‚	22004
@NP	P < 0.05 Tx	22004
@NP	P <	22004
@NP	P	22004
@NP	0.05 Tx	22008
@NP	AdPGIS-OEC Tp versus Tx + OEC Tp ã€‚	22017
@NP	AdPGIS-OEC Tp versus Tx	22017
@NP	AdPGIS-OEC Tp	22017
@NP	Tx	22038
@NP	OEC Tp ã€‚	22043
@NP	OEC Tp	22043
@NP	ã€‚	22049
@NP	Data	22050
@NP	ANOVA followed by LSD test	22072
@NP	ANOVA	22072
@NP	LSD test	22090
@NP	Data	22100
@NP	the mean Â± SEM Fig.	22115
@NP	8 Serotonin immunoreactive nerve fibers and WGA-HRP labelled signals	22136
@NP	8 Serotonin immunoreactive nerve fibers and WGA-HRP	22136
@NP	signals	22197
@NP	the proximal and distal stumps	22222
@NP	AdPGIS-transduced OEC-transplanted spinal cords	22256
@NP	a-c : Serotonin immunoreactivity in the longitudinal section of spinal cord .	22305
@NP	a-c	22305
@NP	Serotonin immunoreactivity in the longitudinal section of spinal cord	22310
@NP	Serotonin immunoreactivity	22310
@NP	the longitudinal section of spinal cord	22340
@NP	the longitudinal section	22340
@NP	spinal cord	22368
@NP	Bar	22381
@NP	50 Î¼m	22387
@NP	d	22394
@NP	&	22396
@NP	WGA-HRP	22401
@NP	signals	22418
@NP	TMB positive staining	22431
@NP	the proximal and distal spinal cords , respectively ,	22456
@NP	the proximal and distal spinal cords	22456
@NP	animals	22511
@NP	AdPGIS-OEC using anterograde WGA-HRP tracing from motor sensory cortex	22532
@NP	AdPGIS-OEC	22532
@NP	anterograde WGA-HRP tracing from motor sensory cortex	22549
@NP	anterograde WGA-HRP	22549
@NP	motor sensory cortex	22582
@NP	Bar	22604
@NP	100 Î¼m	22610
@NP	a and b	22618
@NP	a	22618
@NP	b	22624
@NP	longitudinal sections of proximal cord	22630
@NP	longitudinal sections	22630
@NP	proximal cord	22655
@NP	The dotted line	22670
@NP	the separation between grey and white matter in panel	22695
@NP	the separation	22695
@NP	grey and white matter in panel	22718
@NP	grey and white matter	22718
@NP	panel	22743
@NP	Arrow	22752
@NP	5-HT -LRB- + -RRB-	22767
@NP	5-HT	22767
@NP	+	22772
@NP	fibers	22775
@NP	c	22783
@NP	the	22791
@NP	+	22800
@NP	fibers in the gray matter of OEC-transplanted distal cords	22803
@NP	fibers	22803
@NP	the gray matter of OEC-transplanted distal cords	22813
@NP	longitudinal section	22863
@NP	Inset : higher magnification of boxed inset in -LRB- c -RRB- .	22886
@NP	Inset	22886
@NP	higher magnification of boxed inset in -LRB- c -RRB-	22893
@NP	higher magnification	22893
@NP	boxed inset in -LRB- c -RRB-	22917
@NP	boxed inset in	22917
@NP	c	22933
@NP	d	22937
@NP	transverse sections of T7 -LRB- proximal -RRB- and T12 -LRB- distal -RRB-	22949
@NP	transverse sections	22949
@NP	T7 -LRB- proximal -RRB- and T12 -LRB- distal -RRB-	22972
@NP	T7	22972
@NP	T12	22990
@NP	stumps	23003
@NP	We	23025
@NP	OEC culture	23058
@NP	adult rat olfactory bulb	23075
@NP	confluence	23116
@NP	OEC	23128
@NP	immunocytochemistry	23167
@NP	Histologic analysis of cultured OEC	23188
@NP	Histologic analysis	23188
@NP	cultured OEC	23211
@NP	> 90 % of cells	23238
@NP	> 90 %	23238
@NP	>	23238
@NP	cells	23246
@NP	low affinity nerve growth factor receptor	23275
@NP	p75	23318
@NP	S100	23324
@NP	GFAP	23333
@NP	Fig. 1a-c , 90.8 Â±	23339
@NP	Fig. 1a-c	23339
@NP	90.8 Â±	23350
@NP	2.9 %	23368
@NP	1.3 %	23381
@NP	Hoechst 33258 -LRB- + -RRB- cells	23413
@NP	Hoechst 33258 -LRB- + -RRB-	23413
@NP	Hoechst 33258	23413
@NP	+	23427
@NP	cells	23430
@NP	The infective tropism of recombinant adenovirus in OEC	23438
@NP	The infective tropism	23438
@NP	recombinant adenovirus in OEC	23463
@NP	recombinant adenovirus	23463
@NP	OEC	23489
@NP	AdGFP infection	23508
@NP	AdGFP	23525
@NP	OEC culture	23544
@NP	50 MOI	23561
@NP	transduction of virtually all cultured cells -LRB- Fig. 1d -RRB-	23582
@NP	transduction	23582
@NP	virtually all cultured cells -LRB- Fig. 1d -RRB-	23598
@NP	virtually all	23598
@NP	cells -LRB- Fig. 1d -RRB-	23621
@NP	cells	23621
@NP	Fig. 1d	23628
@NP	This	23638
@NP	OEC	23658
@NP	AdGFP infection	23687
@NP	Our pilot study	23704
@NP	the expressional existence of COX-1 and COX-2 , but not PGIS , in cultured OEC	23733
@NP	the expressional existence of COX-1 and COX-2	23733
@NP	the expressional existence	23733
@NP	COX-1 and COX-2	23763
@NP	PGIS , in cultured OEC	23788
@NP	PGIS	23788
@NP	OEC	23806
@NP	recombinant AdPGIS	23817
@NP	OEC for selective eicosanoid production	23866
@NP	OEC	23866
@NP	selective eicosanoid production	23874
@NP	Recombinant AdPGK	23907
@NP	a -LRB- mock -RRB- vector control	23937
@NP	mock	23940
@NP	2 -- 3 days after AdPGK or AdPGIS infection	23965
@NP	2	23965
@NP	3 days after AdPGK or AdPGIS infection	23967
@NP	3 days	23967
@NP	AdPGK or AdPGIS infection	23980
@NP	the biosynthetic activity of eicosanoid in confluent OEC cultures	24007
@NP	the biosynthetic activity	24007
@NP	eicosanoid in confluent OEC cultures	24036
@NP	eicosanoid	24036
@NP	confluent OEC cultures	24050
@NP	Fig. 2a & b	24087
@NP	Fig. 2a	24087
@NP	b	24097
@NP	the HPLC spectrum of 14C-labelled eicosanoid production	24105
@NP	the HPLC spectrum	24105
@NP	14C-labelled eicosanoid production	24126
@NP	cultured OEC in response	24164
@NP	cultured OEC	24164
@NP	response	24180
@NP	-LSB- 1-14C -RSB- arachidonic acid -LRB- AA -RRB- treatment	24192
@NP	-LSB- 1-14C -RSB-	24192
@NP	AA	24218
@NP	There	24233
@NP	two predominant peaks	24244
@NP	14C-labelled prostaglandin -LRB- PG -RRB- E2	24267
@NP	14C-labelled prostaglandin	24267
@NP	PG	24295
@NP	E2	24299
@NP	AA in nontreated OEC cultures -LRB- Fig. 2a -RRB-	24306
@NP	AA	24306
@NP	nontreated OEC cultures -LRB- Fig. 2a -RRB-	24312
@NP	nontreated OEC cultures	24312
@NP	Fig. 2a	24337
@NP	Very small peak	24347
@NP	prostacyclin	24366
@NP	its hydrolysis product 6-keto - PGF1Î± -LRB- 6KP -RRB-	24389
@NP	its hydrolysis product 6-keto	24389
@NP	PGF1Î±	24420
@NP	6KP	24427
@NP	OEC	24451
@NP	The transduction of AdPGK in cultured OEC	24456
@NP	The transduction	24456
@NP	AdPGK in cultured OEC	24476
@NP	AdPGK	24476
@NP	cultured OEC	24485
@NP	the metabolic profile of -LSB- 1-14C -RSB- AA -LRB- data not shown -RRB-	24512
@NP	the metabolic profile	24512
@NP	-LSB- 1-14C -RSB- AA -LRB- data not shown -RRB-	24537
@NP	-LSB- 1-14C -RSB- AA	24537
@NP	-LSB- 1-14C -RSB-	24537
@NP	data not shown	24549
@NP	data	24549
@NP	AA metabolites	24581
@NP	prostacyclin synthesis on AdPGIS transduction	24617
@NP	prostacyclin synthesis	24617
@NP	AdPGIS transduction	24643
@NP	OEC	24666
@NP	An increased 6KP level with a concurrent decrease of PGE2 level	24671
@NP	An increased 6KP level	24671
@NP	a concurrent decrease of PGE2 level	24699
@NP	a concurrent decrease	24699
@NP	PGE2 level	24724
@NP	AdPGIStransduced OEC cultures -LRB- Fig. 2b -RRB-	24755
@NP	AdPGIStransduced OEC cultures	24755
@NP	Fig. 2b	24786
@NP	This	24796
@NP	the overexpressing PGIS in OEC	24816
@NP	the overexpressing PGIS	24816
@NP	OEC	24843
@NP	prostacyclin	24884
@NP	AA	24902
@NP	Western blot analysis of OEC further	24906
@NP	Western blot analysis	24906
@NP	OEC further	24931
@NP	OEC	24957
@NP	high levels of COX-1 and COX-2 but not PGIS	24971
@NP	high levels of COX-1 and COX-2	24971
@NP	high levels	24971
@NP	COX-1 and COX-2	24986
@NP	PGIS	25010
@NP	AdPGIS infection	25019
@NP	expression of PGIS	25037
@NP	expression	25037
@NP	PGIS	25051
@NP	Fig. 2c	25071
@NP	Beneficial effect of OEC or PGIS-overexpressing OEC -LRB- PGIS-OEC -RRB-	25081
@NP	Beneficial effect	25081
@NP	OEC or PGIS-overexpressing OEC -LRB- PGIS-OEC -RRB-	25102
@NP	OEC or PGIS-overexpressing OEC	25102
@NP	PGIS-OEC	25134
@NP	co-culture of OEC	25166
@NP	co-culture	25166
@NP	OEC	25180
@NP	cortical neuron-glial cultures	25189
@NP	treatment with OGD , an in vitro ischemia	25226
@NP	treatment	25226
@NP	OGD , an in vitro ischemia	25241
@NP	OGD	25241
@NP	an in vitro ischemia	25246
@NP	ischemia	25258
@NP	Neuron-glial cultures	25268
@NP	3 h of OGD stress	25300
@NP	3 h	25300
@NP	OGD stress	25307
@NP	normoxic condition	25334
@NP	OEC or PGIS-OEC -LRB- seeded in Millicell insert well -RRB-	25354
@NP	OEC or PGIS-OEC	25354
@NP	Millicell insert	25381
@NP	these stressed neuron-glial culture and further incubated for 2 days	25428
@NP	these stressed neuron-glial culture	25428
@NP	further incubated for 2 days	25468
@NP	further	25468
@NP	2 days	25490
@NP	Fig. 3a-c	25498
@NP	the stressed neurons	25519
@NP	tubulin-IR	25581
@NP	both OEC and PGIS-OEC co-cultures	25596
@NP	neuron-glial cultures only	25643
@NP	neuron-glial cultures	25643
@NP	The relative density of tubulin-IR in both co-cultures	25671
@NP	The relative density	25671
@NP	tubulin-IR	25695
@NP	co-cultures	25714
@NP	those in neuron-glial cultures only -LRB- Fig. 3g ; P < 0.01 -RRB-	25757
@NP	those in neuron-glial cultures only	25757
@NP	those	25757
@NP	neuron-glial cultures	25766
@NP	Fig. 3g ; P < 0.01	25794
@NP	Fig. 3g	25794
@NP	P < 0.01	25803
@NP	P <	25803
@NP	P	25803
@NP	0.01	25807
@NP	the neuronal densities between these two OEC-treated groups	25823
@NP	the neuronal densities	25823
@NP	these two OEC-treated groups	25854
@NP	no difference -LRB- Fig. 3g -RRB-	25888
@NP	no difference	25888
@NP	Fig. 3g	25903
@NP	PI	25927
@NP	+	25931
@NP	cells	25934
@NP	both OEC co-culture	25943
@NP	groups	25963
@NP	those	25999
@NP	neuron-glial cultures only -LRB- Fig. 3d-f and h ; P < 0.01 or 0.05 -RRB-	26008
@NP	neuron-glial cultures only	26008
@NP	neuron-glial cultures	26008
@NP	Fig. 3d-f and h ; P < 0.01 or 0.05	26036
@NP	Fig. 3d-f and h	26036
@NP	P < 0.01 or 0.05	26053
@NP	P	26053
@NP	< 0.01 or 0.05	26055
@NP	<	26055
@NP	This result	26072
@NP	OEC cocultures	26099
@NP	neuronal cells	26136
@NP	OGD-induced damage	26156
@NP	We	26176
@NP	the effect of OEC or PGIS-OEC insert on neuron or microglia	26193
@NP	the effect of OEC	26193
@NP	the effect	26193
@NP	OEC	26207
@NP	PGIS-OEC insert on neuron or microglia	26214
@NP	PGIS-OEC insert	26214
@NP	neuron or microglia	26233
@NP	spinal cord neuron-glial cultures	26256
@NP	spinal cord	26256
@NP	neuron-glial cultures	26268
@NP	Fig. 4a-c & g	26303
@NP	Fig. 4a-c	26303
@NP	g	26315
@NP	neuronal connection -LRB- tubulin - IR density -RRB-	26318
@NP	neuronal connection	26318
@NP	tubulin - IR density	26339
@NP	tubulin	26339
@NP	IR density	26348
@NP	PGIS-OEC cocultures	26388
@NP	that in neuron-glial cultures only	26421
@NP	that	26421
@NP	neuron-glial cultures only	26429
@NP	neuron-glial cultures	26429
@NP	its co-culture with OEC -LRB- P < 0.05 or 0.01 -RRB-	26459
@NP	its co-culture	26459
@NP	OEC -LRB- P < 0.05 or 0.01 -RRB-	26479
@NP	OEC	26479
@NP	P < 0.05 or 0.01	26484
@NP	P	26484
@NP	< 0.05 or 0.01	26486
@NP	<	26486
@NP	contrast	26506
@NP	ED1-IR-microglial number in neuron-glial cultures	26516
@NP	ED1-IR-microglial number	26516
@NP	neuron-glial cultures	26544
@NP	PGIS-OEC co-cultures	26595
@NP	that	26629
@NP	neuron-glial cultures	26637
@NP	OEC co-culture -LRB- P < 0.01 -RRB- -LRB- Fig. 4d-f & h -RRB-	26670
@NP	OEC co-culture -LRB- P < 0.01 -RRB-	26670
@NP	OEC co-culture	26670
@NP	P < 0.01	26686
@NP	P	26686
@NP	< 0.01	26688
@NP	<	26688
@NP	0.01	26690
@NP	Fig. 4d-f & h	26697
@NP	Fig. 4d-f	26697
@NP	h	26709
@NP	The in vivo growth-promoting properties of OEC or PGIS-OEC	26713
@NP	The in vivo growth-promoting properties of OEC	26713
@NP	growth-promoting properties of OEC	26725
@NP	growth-promoting properties	26725
@NP	OEC	26756
@NP	PGIS-OEC	26763
@NP	transplantation of each OEC	26793
@NP	transplantation	26793
@NP	each OEC	26812
@NP	the complete T8-transected cavities of rat spinal cords	26824
@NP	the complete T8-transected cavities	26824
@NP	rat spinal cords	26863
@NP	Adult OEC	26881
@NP	GFP or PGIS	26916
@NP	adenovirus-mediated gene transfer	26931
@NP	AdGFP - or AdPGISinfected OEC in fibrin solution were then applied to the	26966
@NP	AdGFP	26966
@NP	AdPGISinfected OEC in fibrin solution were then applied to the	26976
@NP	AdPGISinfected OEC	26976
@NP	fibrin solution were then applied to the	26998
@NP	fibrin solution	26998
@NP	the	27035
@NP	cavity -LRB- 5 mm gap -RRB- of spinal cord	27050
@NP	cavity -LRB- 5 mm gap -RRB-	27050
@NP	cavity	27050
@NP	5 mm gap	27058
@NP	spinal cord	27071
@NP	thoracic level 8 , as shown in Fig. 5a-c	27086
@NP	thoracic level 8	27086
@NP	Fig. 5a-c	27116
@NP	Figure .	27127
@NP	5b	27135
@NP	a complete transection of T8	27144
@NP	a complete transection	27144
@NP	T8	27170
@NP	a 5 mm gap	27178
@NP	Fig. 5c	27190
@NP	fibrin-mixed OEC	27204
@NP	the transected T8 gap	27236
@NP	the	27236
@NP	T8 gap	27251
@NP	OEC graft in vivo	27268
@NP	OEC graft	27268
@NP	vivo	27281
@NP	the AdGFP-infected OEC transplanted SCI rats	27287
@NP	the AdGFP-infected OEC	27287
@NP	SCI rats	27323
@NP	the first , third , fifth , eighth and twelfth week after surgery	27364
@NP	the first , third , fifth , eighth and twelfth week	27364
@NP	surgery	27419
@NP	Fig. 5d-f	27428
@NP	GFPimmunoreactive OEC	27444
@NP	the longitudinal spinal section -LRB- T7 ~ T9 -RRB-	27469
@NP	the longitudinal spinal section	27469
@NP	T7 ~ T9	27502
@NP	AdGFP-infected OEC grafted SCI rats	27514
@NP	AdGFP-infected OEC	27514
@NP	SCI rats	27541
@NP	one week postgraft	27554
@NP	+	27579
@NP	the transected cavity -LRB- Fig. 5d -RRB-	27600
@NP	the transected cavity	27600
@NP	Fig. 5d	27623
@NP	regions close to both spinal stumps -LRB- marked with stars in Fig. 5e & f -RRB-	27639
@NP	regions close to both spinal stumps	27639
@NP	regions	27639
@NP	both spinal stumps	27656
@NP	stars in Fig. 5e & f	27688
@NP	stars	27688
@NP	Fig. 5e & f	27697
@NP	Fig. 5e	27697
@NP	f	27707
@NP	the cells	27715
@NP	the rostral/caudal stumps of the spinal cord	27746
@NP	the rostral/caudal stumps	27746
@NP	the spinal cord	27775
@NP	We	27792
@NP	any	27810
@NP	+	27819
@NP	OEC in the grafted site at third weeks post-graft onwards in SCI rats	27822
@NP	OEC	27822
@NP	the grafted site at third weeks post-graft onwards in SCI rats	27829
@NP	the grafted site	27829
@NP	third weeks post-graft onwards in SCI rats	27849
@NP	third weeks	27849
@NP	post-graft onwards in SCI rats	27861
@NP	post-graft onwards	27861
@NP	SCI rats	27883
@NP	OEC	27901
@NP	spinal cord stumps	27924
@NP	GFP -LRB- + -RRB- OEC was	27957
@NP	GFP	27957
@NP	+	27962
@NP	both rostral/caudal stumps of the spinal cord about 4 -- 5 mm	27982
@NP	rostral/caudal stumps of the spinal cord about 4	27987
@NP	rostral/caudal stumps	27987
@NP	the spinal cord about 4	28012
@NP	the spinal cord	28012
@NP	4	28034
@NP	5 mm	28036
@NP	the injured epicenter at third weeks post-graft -LRB- Fig. 5g-i -RRB-	28051
@NP	the injured epicenter at third weeks post-graft	28051
@NP	the injured epicenter at third weeks	28051
@NP	the injured epicenter	28051
@NP	third weeks	28076
@NP	Fig. 5g-i	28100
@NP	the effects of prostacyclin	28123
@NP	the effects	28123
@NP	prostacyclin	28138
@NP	inflammatory cells	28154
@NP	Iba1-immunoreactive microglia	28174
@NP	the 3 week	28207
@NP	spinal cords of the AdGFP-OEC-grafted and AdPGIS-OEC-grafted groups	28226
@NP	spinal cords	28226
@NP	the AdGFP-OEC-grafted and AdPGIS-OEC-grafted groups	28242
@NP	the AdGFP-OEC-grafted	28242
@NP	AdPGIS-OEC-grafted groups	28268
@NP	Fig. 6 Iba1 immunoreactivity	28321
@NP	the rostral/caudal stumps of two groups	28372
@NP	the rostral/caudal stumps	28372
@NP	two groups	28401
@NP	relative few Iba1 immunoreactivity	28421
@NP	the transection gap	28469
@NP	Microglial cells in the rostral/caudal stumps of AdPGIS-OEC grafted spinal cords	28490
@NP	Microglial cells	28490
@NP	the rostral/caudal stumps of AdPGIS-OEC grafted spinal cords	28510
@NP	the rostral/caudal stumps	28510
@NP	AdPGIS-OEC grafted spinal cords	28539
@NP	AdPGIS-OEC	28539
@NP	spinal cords	28558
@NP	less immunoreactivity	28576
@NP	that of AdGFP-OEC grafted spinal cords	28603
@NP	that	28603
@NP	AdGFP-OEC grafted spinal cords	28611
@NP	AdGFP-OEC	28611
@NP	spinal cords	28629
@NP	transected gap	28654
@NP	microglial cells	28670
@NP	similar immunocreactivity	28692
@NP	AdPGIS-OEC-grafted and AdGFP-OEC-grafted spinal cords	28726
@NP	AdPGIS-OEC-grafted	28726
@NP	AdGFP-OEC-grafted spinal cords	28749
@NP	all experimental rats receiving similar degrees of injury	28791
@NP	all experimental rats	28791
@NP	similar degrees of injury	28823
@NP	similar degrees	28823
@NP	injury	28842
@NP	the rate of their recovery	28864
@NP	the rate	28864
@NP	their recovery	28876
@NP	the rats	28892
@NP	hindlimb locomotor functional assessment	28919
@NP	BBB and CBS scores	28963
@NP	Fig. 7a	28995
@NP	OEC transplant	29004
@NP	functional recovery	29027
@NP	rats	29050
@NP	a complete transection injury in spinal cord	29061
@NP	a complete transection injury	29061
@NP	spinal cord	29094
@NP	The BBB scores of the SCI rats receiving OEC and AdPGIS-OEC	29107
@NP	The BBB scores	29107
@NP	the SCI rats receiving OEC and AdPGIS-OEC	29125
@NP	the SCI rats	29125
@NP	OEC and AdPGIS-OEC	29148
@NP	that in SCI rats	29184
@NP	that	29184
@NP	SCI rats	29192
@NP	vehicle treatment -LRB- BBB scores 2 -- 5 -RRB-	29206
@NP	vehicle treatment	29206
@NP	BBB scores 2 -- 5	29225
@NP	BBB scores	29225
@NP	2 -- 5	29236
@NP	The values	29243
@NP	those observed in SCI rats with vehicle treatment -LRB- BBB scores < 1 -RRB-	29288
@NP	those	29288
@NP	SCI rats	29306
@NP	vehicle treatment -LRB- BBB scores < 1 -RRB-	29320
@NP	vehicle treatment	29320
@NP	BBB scores < 1	29339
@NP	BBB scores	29339
@NP	< 1	29350
@NP	<	29350
@NP	1	29351
@NP	The BBB scores in vehicle-treated rats	29355
@NP	The BBB scores	29355
@NP	vehicle-treated rats	29373
@NP	those shown by our previous studies -LSB- 1 , 2 , 39 -RSB-	29410
@NP	those	29410
@NP	our previous studies	29425
@NP	-LSB- 1 , 2 , 39 -RSB-	29446
@NP	6 weeks through 12 weeks	29472
@NP	6 weeks	29472
@NP	12 weeks	29488
@NP	post-graft , OEC or AdPGIS-OEC treatment	29497
@NP	the hindlimb function of SCI rats -LRB- all P < 0.05 -RRB-	29560
@NP	the hindlimb function	29560
@NP	SCI rats -LRB- all P < 0.05 -RRB-	29585
@NP	SCI rats	29585
@NP	all P < 0.05	29595
@NP	all P <	29595
@NP	0.05	29603
@NP	The BBB scores of OEC or AdPGIS-OEC	29610
@NP	The BBB scores	29610
@NP	OEC or AdPGIS-OEC	29628
@NP	each other until 12 week post graft -LRB- P < 0.05 -RRB-	29670
@NP	each other until 12 week post graft	29670
@NP	12 week	29687
@NP	P < 0.05	29707
@NP	P	29707
@NP	< 0.05	29709
@NP	<	29709
@NP	0.05	29711
@NP	The locomotion in SCI rats receiving AdPGIS-OEC	29718
@NP	The locomotion	29718
@NP	SCI rats receiving AdPGIS-OEC	29736
@NP	SCI rats	29736
@NP	AdPGIS-OEC	29755
@NP	12 week post SCI	29782
@NP	significant increase	29804
@NP	BBB score -LRB- BBB : 5.2 Â± 0.7 , Fig. 7a -RRB-	29828
@NP	BBB score	29828
@NP	BBB : 5.2 Â± 0.7 , Fig. 7a	29839
@NP	BBB	29839
@NP	5.2 Â± 0.7 , Fig. 7a	29843
@NP	5.2 Â± 0.7	29843
@NP	Fig. 7a	29854
@NP	that in OEC graft only -LRB- BBB : 3.4 Â± 0.5 -RRB-	29868
@NP	that in OEC graft only	29868
@NP	that	29868
@NP	OEC graft	29876
@NP	BBB : 3.4 Â± 0.5	29892
@NP	BBB	29892
@NP	3.4 Â± 0.5	29896
@NP	3.4 Â±	29896
@NP	0.5	29902
@NP	Fig. 7b	29908
@NP	the scatter plot of BBB scores of each SCI rat	29924
@NP	the scatter plot	29924
@NP	BBB scores of each SCI rat	29944
@NP	BBB scores	29944
@NP	each SCI rat	29958
@NP	none , OEC graft or AdPGIS-OEC graft	29981
@NP	none	29981
@NP	OEC graft	29987
@NP	AdPGIS-OEC graft	30000
@NP	12 weeks post treatment	30020
@NP	Fig. 7c	30045
@NP	CBS scores of these experimental rats	30059
@NP	CBS scores	30059
@NP	these experimental rats	30073
@NP	non-treated group	30110
@NP	the experimental groups that received OEC or AdPGISOEC transplantation	30129
@NP	the experimental groups	30129
@NP	OEC or AdPGISOEC transplantation	30167
@NP	better restoration	30209
@NP	SCI rats with OEC or AdPGIS-OEC grafts	30229
@NP	SCI rats	30229
@NP	OEC or AdPGIS-OEC grafts	30243
@NP	improvement -LRB- significantly lower CBS score -RRB-	30277
@NP	improvement	30277
@NP	CBS score	30310
@NP	combined behavior function than vehicle-treated SCI rats -LRB- P < 0.05 -RRB-	30324
@NP	combined behavior function	30324
@NP	vehicle-treated SCI rats -LRB- P < 0.05 -RRB-	30356
@NP	vehicle-treated SCI rats	30356
@NP	P < 0.05	30382
@NP	P	30382
@NP	< 0.05	30384
@NP	<	30384
@NP	0.05	30386
@NP	10 & 12 week postgraft	30396
@NP	10	30396
@NP	12 week postgraft	30401
@NP	the CBS of AdPGIS-OEC grafted SCI rats	30420
@NP	the CBS	30420
@NP	AdPGIS-OEC grafted SCI rats	30431
@NP	AdPGIS-OEC	30431
@NP	SCI rats	30450
@NP	that of OEC grafted SCI rats -LRB- P < 0.05 -RRB-	30493
@NP	that	30493
@NP	OEC grafted SCI rats -LRB- P < 0.05 -RRB-	30501
@NP	OEC	30501
@NP	SCI rats -LRB- P < 0.05 -RRB-	30513
@NP	SCI rats	30513
@NP	P < 0.05	30523
@NP	P	30523
@NP	< 0.05	30525
@NP	<	30525
@NP	0.05	30527
@NP	none of the animals	30543
@NP	none	30543
@NP	the animals	30551
@NP	movements of fore and hind limbs or the ability	30588
@NP	movements	30588
@NP	fore and hind limbs or the ability	30601
@NP	fore and hind limbs	30601
@NP	the ability	30624
@NP	weight	30644
@NP	the hind limbs	30654
@NP	12 weeks post injury and treatment	30673
@NP	12 weeks	30673
@NP	rats	30709
@NP	histological analysis or anterograde	30732
@NP	histological analysis	30732
@NP	anterograde	30757
@NP	neural regeneration	30791
@NP	Fig. 8a-b	30812
@NP	typical serotonin immunoreactive fibers in the proximal stump of OEC	30828
@NP	typical serotonin immunoreactive fibers	30828
@NP	the proximal stump of OEC	30871
@NP	the proximal stump	30871
@NP	OEC	30893
@NP	AdPGIS-OEC-grafted spinal cord	30901
@NP	Fig. 8c	30933
@NP	a few	30947
@NP	5-HT fibers	30966
@NP	the distal stump of OEC-grafted spinal cord	30981
@NP	the distal stump	30981
@NP	OEC-grafted spinal cord	31001
@NP	Such serotonergic axons in the distal cord	31026
@NP	Such serotonergic axons	31026
@NP	the distal cord	31053
@NP	one	31086
@NP	six OECtransplanted SCI rats -LRB- 16.7 % -RRB-	31097
@NP	six OECtransplanted SCI rats	31097
@NP	16.7 %	31127
@NP	three	31138
@NP	five AdPGIS-OEC transplanted SCI rats -LRB- 60 % -RRB-	31151
@NP	five AdPGIS-OEC	31151
@NP	SCI rats -LRB- 60 % -RRB-	31180
@NP	SCI rats	31180
@NP	60 %	31190
@NP	the WGA anterograde	31206
@NP	results	31234
@NP	Fig. 8d	31243
@NP	the	31264
@NP	+	31273
@NP	staining fibers	31276
@NP	corticospinal tract	31295
@NP	the -LRB- intact , thoracic T7 -RRB- proximal stump	31318
@NP	intact	31323
@NP	thoracic T7	31331
@NP	AdPGISOEC - grafted spinal cord	31362
@NP	AdPGISOEC	31362
@NP	spinal cord	31381
@NP	A few	31394
@NP	TMB	31413
@NP	+	31418
@NP	staining	31421
@NP	-LRB- arrow -RRB- fibers	31430
@NP	-LRB- arrow -RRB-	31430
@NP	fibers	31438
@NP	the distal stump -LRB- at thoracic T12 ; Fig. 8e -RRB- of two out of six	31459
@NP	the distal stump -LRB- at thoracic T12 ; Fig. 8e -RRB-	31459
@NP	the distal stump	31459
@NP	thoracic T12 ; Fig. 8e	31480
@NP	thoracic T12	31480
@NP	Fig. 8e	31494
@NP	two	31506
@NP	six	31517
@NP	AdPGIS-OECgraft SCI rats -LRB- 40 % -RRB-	31521
@NP	AdPGIS-OECgraft SCI rats	31521
@NP	40 %	31547
@NP	Nothing	31553
@NP	the distal stump of transected SCI rats	31579
@NP	the distal stump	31579
@NP	transected SCI rats	31599
@NP	Table 1	31620
@NP	the corresponding results	31636
@NP	animal behavior	31665
@NP	neuronal	31682
@NP	WGA-HRP and serotonin immunoreactivity	31702
@NP	12 weeks after injury and treatment	31744
@NP	12 weeks	31744
@NP	injury and treatment	31759
@NP	Discussion	31781
@NP	The central observation of this study	31792
@NP	The central observation	31792
@NP	this study	31819
@NP	overexpression of prostacyclin synthetase in OEC	31838
@NP	overexpression	31838
@NP	prostacyclin synthetase in OEC	31856
@NP	prostacyclin synthetase	31856
@NP	OEC	31883
@NP	Ad gene transfer	31904
@NP	prostacyclin synthesis	31942
@NP	other eicosanoid levels	31990
@NP	This PGIS overexpressing OEC	32015
@NP	good neuroregenerative potential in cortical or spinal neuron-glial cultures	32048
@NP	good neuroregenerative potential	32048
@NP	cortical or spinal neuron-glial cultures	32084
@NP	Further in vivo studies	32126
@NP	vivo	32137
@NP	transplantation of OEC to the injured site in SCI rats	32162
@NP	transplantation	32162
@NP	OEC to the injured site in SCI rats	32181
@NP	OEC	32181
@NP	the injured site in SCI rats	32188
@NP	the injured site	32188
@NP	SCI rats	32208
@NP	axonal regeneration	32229
@NP	a 5 mm transection gap	32256
@NP	hindlimb function	32292
@NP	Transplantation of AdPGIS-transduced OEC to T8-transected rats	32311
@NP	Transplantation	32311
@NP	AdPGIS-transduced OEC to T8-transected rats	32330
@NP	AdPGIS-transduced OEC	32330
@NP	T8-transected rats	32355
@NP	fiber tract regeneration	32391
@NP	the functional outcome	32443
@NP	We	32467
@NP	evidence of axonal regeneration	32481
@NP	evidence	32481
@NP	axonal regeneration	32493
@NP	a complete spinal cord transection in 40 % of AdPGIS-OEC spinal rats	32520
@NP	a complete spinal cord transection	32520
@NP	40 % of AdPGIS-OEC spinal rats	32558
@NP	40 %	32558
@NP	AdPGIS-OEC spinal rats	32565
@NP	anterograde WGA	32591
@NP	motor sensory cortex	32620
@NP	serotonergic axons	32655
@NP	the distal cord	32677
@NP	one of OEC-transplanted rats -LRB- 16.7 % -RRB-	32715
@NP	one	32715
@NP	OEC-transplanted rats -LRB- 16.7 % -RRB-	32722
@NP	OEC-transplanted rats	32722
@NP	16.7 %	32745
@NP	three of AdPGIS-OEC transplanted rats -LRB- 60 % -RRB-	32756
@NP	three	32756
@NP	AdPGIS-OEC transplanted rats -LRB- 60 % -RRB-	32765
@NP	AdPGIS-OEC transplanted rats	32765
@NP	60 %	32795
@NP	Nothing	32801
@NP	the transected SCI rats	32822
@NP	We	32847
@NP	adult OEC cultures	32867
@NP	their unique seeding properties	32889
@NP	plastic dish	32924
@NP	More than 90 % of these cells	32938
@NP	More than 90 %	32938
@NP	these cells	32955
@NP	S100 and p75 , the low affinity nerve growth receptor	32990
@NP	S100 and p75	32990
@NP	the low affinity nerve growth receptor	33004
@NP	This	33044
@NP	the reported characteristic	33068
@NP	OEC	33099
@NP	a specialized glia with both Schwann cell-like and astrocyte-like properties	33104
@NP	a specialized glia	33104
@NP	both Schwann cell-like and astrocyte-like properties	33128
@NP	Schwann cell-like	33133
@NP	Schwann	33133
@NP	cell-like	33141
@NP	astrocyte-like properties	33155
@NP	-LSB- 17 , 34 , 42 -RSB-	33181
@NP	We	33195
@NP	OEC	33226
@NP	exogenous arachidonic acid	33251
@NP	PGE2 , a COX-1 - or COX-2 - derived product	33283
@NP	PGE2	33283
@NP	a COX-1 - or COX-2 - derived product	33289
@NP	a COX-1 - or COX-2 -	33289
@NP	a COX-1	33289
@NP	COX-2	33301
@NP	product	33316
@NP	The high AA metabolic activity of OEC	33325
@NP	The high AA metabolic activity	33325
@NP	OEC	33359
@NP	that of astrocytes reported in our recent article -LSB- 29 -RSB-	33383
@NP	that	33383
@NP	astrocytes reported in our recent article -LSB- 29 -RSB-	33391
@NP	astrocytes	33391
@NP	our recent article -LSB- 29 -RSB-	33414
@NP	our recent article	33414
@NP	29 -RSB-	33434
@NP	this	33448
@NP	contrast	33459
@NP	low AA metabolic activity	33471
@NP	neuron-glial cells , which released barely detected eicosanoids -LSB- 28 -RSB-	33500
@NP	neuron-glial cells	33500
@NP	eicosanoids -LSB- 28 -RSB-	33551
@NP	eicosanoids	33551
@NP	28 -RSB-	33564
@NP	gene transfer of AdPGIS to OEC	33584
@NP	gene transfer	33584
@NP	AdPGIS to OEC	33601
@NP	AdPGIS	33601
@NP	OEC	33611
@NP	the AA catabolism	33623
@NP	synthesis of 6	33649
@NP	synthesis	33649
@NP	6	33662
@NP	keto-PGF1Î±	33665
@NP	a hydrolyzed product of prostacyclin and the production of other eicosanoids	33677
@NP	a hydrolyzed product of prostacyclin	33677
@NP	a hydrolyzed product	33677
@NP	prostacyclin	33701
@NP	the production of other eicosanoids	33718
@NP	the production	33718
@NP	other eicosanoids	33736
@NP	Fig. 2	33780
@NP	This	33789
@NP	the overexpressing PGIS	33809
@NP	cooperation	33860
@NP	endogenous COX	33877
@NP	prostacyclin	33903
@NP	Prostacyclin	33917
@NP	the most potent inhibitor	33933
@NP	platelet aggregation and a cytoprotective agent	33962
@NP	platelet aggregation	33962
@NP	a cytoprotective agent	33987
@NP	various stresses	34018
@NP	-LSB- 21 , 22	34035
@NP	it	34054
@NP	biological half-life time	34079
@NP	only 2 -- 3 min	34111
@NP	only 2	34111
@NP	3 min	34118
@NP	Prostacyclin	34125
@NP	the blood vessels	34156
@NP	the activity of white blood cell and monocyte in the inflammatory reaction	34187
@NP	the activity of white blood cell	34187
@NP	the activity	34187
@NP	white blood cell	34203
@NP	monocyte in the inflammatory reaction	34224
@NP	monocyte	34224
@NP	the inflammatory reaction	34236
@NP	Many studies	34263
@NP	cytoprotective effects of prostacyclin	34283
@NP	cytoprotective effects	34283
@NP	prostacyclin	34309
@NP	the mechanism	34327
@NP	Cytoprotective effects of prostacyclin	34366
@NP	Cytoprotective effects	34366
@NP	prostacyclin	34392
@NP	the function of removing reactive oxygen species -LSB- 43 -RSB-	34419
@NP	the function	34419
@NP	reactive oxygen species	34444
@NP	43 -RSB-	34469
@NP	Prostacyclin	34474
@NP	certain protective function	34491
@NP	spinal cord injury	34523
@NP	it	34557
@NP	other PGs	34573
@NP	the function of vasoconstriction and platelet aggregation	34594
@NP	the function	34594
@NP	vasoconstriction and platelet aggregation	34610
@NP	-LSB- 31 , 44	34652
@NP	Prostacyclin	34662
@NP	inflammatory cells	34689
@NP	the injured tissues	34728
@NP	local inflammatory reaction	34763
@NP	-LSB- 28 , 29 -RSB-	34791
@NP	The functional characterization of OEC	34801
@NP	The functional characterization	34801
@NP	OEC	34836
@NP	co-culture	34865
@NP	neuron-glial cultures	34881
@NP	A clear neuroprotective effect of OEC	34904
@NP	A clear neuroprotective effect	34904
@NP	OEC	34938
@NP	OGDtreated cortical neuron-glial cells	34958
@NP	Both control OEC and PGIS-OEC	34998
@NP	cell death	35048
@NP	neuronal survival	35072
@NP	Such properties of OECs	35091
@NP	Such properties	35091
@NP	OECs	35110
@NP	them	35128
@NP	potential clinical agents able to support injured CNS	35133
@NP	potential clinical agents	35133
@NP	injured CNS	35175
@NP	co-culture with spinal cord neuron-glial cultures	35191
@NP	co-culture	35191
@NP	spinal cord neuron-glial cultures	35207
@NP	spinal cord	35207
@NP	neuron-glial cultures	35219
@NP	PGIS-OEC	35242
@NP	neuronal connection significantly better	35260
@NP	neuronal connection	35260
@NP	OEC	35306
@NP	contrast	35314
@NP	microglial number in neuron-glial cultures	35324
@NP	microglial number	35324
@NP	neuron-glial cultures	35345
@NP	PGIS-OEC co-cultures	35396
@NP	three week PGIS-OEC grafted spinal cords	35421
@NP	three week PGIS-OEC	35421
@NP	spinal cords	35449
@NP	microglial numbers	35463
@NP	those	35507
@NP	GFP-OEC	35516
@NP	spinal cords -LRB- Fig. 6 -RRB-	35532
@NP	spinal cords	35532
@NP	Fig. 6	35546
@NP	co-culture study and our previous report	35571
@NP	co-culture study	35571
@NP	our previous report	35592
@NP	28 -RSB-	35613
@NP	The prostacyclin receptor -LRB- IP receptor -RRB-	35618
@NP	The prostacyclin receptor	35618
@NP	IP receptor	35645
@NP	a G protein	35661
@NP	coupled receptor	35674
@NP	the activation	35720
@NP	adenylate cyclase	35738
@NP	the formation of 3 â€² ,5 â€² cyclic adenosine monophosphate -LRB- cAMP -RRB-	35773
@NP	the formation	35773
@NP	3 â€² ,5 â€² cyclic adenosine monophosphate -LRB- cAMP -RRB-	35790
@NP	3 â€² ,5 â€² cyclic adenosine monophosphate	35790
@NP	3 â€² ,5 â€²	35790
@NP	cAMP	35828
@NP	a key messenger for axon regeneration	35835
@NP	a key messenger	35835
@NP	axon regeneration	35855
@NP	The benificial effect of PGIS-OEC in co-cultures or in grafted spinal cord	35874
@NP	The benificial effect	35874
@NP	PGIS-OEC in co-cultures or in grafted spinal cord	35899
@NP	PGIS-OEC	35899
@NP	co-cultures	35911
@NP	grafted spinal cord	35929
@NP	part	35960
@NP	increase of celllar cAMP	35983
@NP	increase	35983
@NP	celllar cAMP	35995
@NP	microglial activation/infiltration	36018
@NP	prostacyclin	36056
@NP	another possible effect	36072
@NP	microglia	36104
@NP	a pivotal role in inflammatory reaction	36120
@NP	a pivotal role	36120
@NP	inflammatory reaction	36138
@NP	the suggested effects from our previous reports	36164
@NP	the suggested effects	36164
@NP	our previous reports	36191
@NP	-LSB- 28 , 29 -RSB-	36212
@NP	it	36231
@NP	receptor subtype of prostacyclin -LRB- IP1 or IP2 -RRB-	36265
@NP	receptor subtype	36265
@NP	prostacyclin -LRB- IP1 or IP2 -RRB-	36285
@NP	prostacyclin	36285
@NP	IP1 or IP2	36299
@NP	IP1	36299
@NP	IP2	36306
@NP	these effects	36326
@NP	Further studies	36341
@NP	the role	36381
@NP	downstream molecules in the inhibition of microglial number/activation	36400
@NP	downstream molecules	36400
@NP	the inhibition of microglial number/activation	36424
@NP	the inhibition	36424
@NP	microglial number/activation	36442
@NP	adult rat suffered from spinal cord injury	36478
@NP	adult rat	36478
@NP	spinal cord injury	36502
@NP	5-10 %	36522
@NP	fibers at the lesion center	36535
@NP	fibers	36535
@NP	the lesion center	36545
@NP	partially or fully functional recovery in the paralyzed hind limbs	36574
@NP	fully functional recovery in the paralyzed hind	36587
@NP	fully functional recovery	36587
@NP	the paralyzed hind	36616
@NP	rats -LSB- 45 -RSB-	36644
@NP	rats	36644
@NP	45 -RSB-	36650
@NP	we	36666
@NP	the model of severe SCI	36675
@NP	the model	36675
@NP	severe SCI	36688
@NP	complete transection	36704
@NP	the effect of the experimental therapy	36737
@NP	the effect	36737
@NP	the experimental therapy	36751
@NP	This study	36777
@NP	spinal cord	36805
@NP	5 mm segment of the spinal cord being removed	36848
@NP	5 mm segment	36848
@NP	the spinal cord being removed	36864
@NP	the spinal cord	36864
@NP	it	36904
@NP	OEC	36929
@NP	stumps	36938
@NP	the distance between two stumps	36951
@NP	the distance	36951
@NP	two stumps	36972
@NP	5 mm	36987
@NP	Fibrin glue	36993
@NP	a bridge to connect CNS tissue -LSB- 46 -RSB-	37022
@NP	CNS tissue -LSB- 46 -RSB-	37042
@NP	CNS tissue	37042
@NP	46 -RSB-	37054
@NP	the present study	37062
@NP	fibrin glue	37081
@NP	the transplanted OEC	37116
@NP	two spinal stumps	37151
@NP	The OEC embedded in fibrin glue	37170
@NP	The OEC	37170
@NP	fibrin glue	37190
@NP	new regenerating axon re-grow into the distal stump of spinal cord	37213
@NP	new regenerating axon re-grow	37213
@NP	the distal stump of spinal cord	37248
@NP	the distal stump	37248
@NP	spinal cord	37268
@NP	Previous studies	37281
@NP	OEC graft	37313
@NP	the host spinal cord	37340
@NP	axon	37383
@NP	-LSB- 17 , 47 -RSB-	37388
@NP	the fibrin glue-mixed OEC	37421
@NP	the host spinal cord	37476
@NP	we	37498
@NP	AdGFP gene transfer	37509
@NP	OEC	37532
@NP	cell grafting	37543
@NP	The result	37558
@NP	OEC expressing GFP	37581
@NP	OEC	37581
@NP	GFP	37596
@NP	one and three weeks after surgery	37618
@NP	one and three weeks	37618
@NP	surgery	37644
@NP	one week postgraft	37656
@NP	OEC	37676
@NP	the transplanted site and the edge of the transplanted area	37699
@NP	the transplanted site	37699
@NP	the edge of the transplanted area	37725
@NP	the edge	37725
@NP	the transplanted area	37737
@NP	the cells	37764
@NP	the rostral/caudal stumps of the spinal cord	37795
@NP	the rostral/caudal stumps	37795
@NP	the spinal cord	37824
@NP	the result of Ruitenberg -LSB- 48 -RSB-	37857
@NP	the result	37857
@NP	Ruitenberg -LSB- 48 -RSB-	37871
@NP	Ruitenberg	37871
@NP	48 -RSB-	37883
@NP	OEC	37896
@NP	spinal cord stumps	37914
@NP	three weeks postgraft	37936
@NP	GFP	37972
@NP	+	37977
@NP	both rostral/caudal stumps of the spinal cord about 4 -- 5 mm	37997
@NP	rostral/caudal stumps of the spinal cord about 4	38002
@NP	rostral/caudal stumps	38002
@NP	the spinal cord about 4	38027
@NP	the spinal cord	38027
@NP	4	38049
@NP	5 mm	38051
@NP	the injured epicenter at third weeks	38066
@NP	the injured epicenter	38066
@NP	third weeks	38091
@NP	post-graft -LRB- Fig. 5g-i -RRB- ,	38103
@NP	post-graft	38103
@NP	Fig. 5g-i	38115
@NP	our previous result	38139
@NP	34 -RSB-	38160
@NP	It	38165
@NP	OEC in the injured epicenter	38197
@NP	OEC	38197
@NP	the injured epicenter	38204
@NP	apoptosis	38236
@NP	OEC that migrated into the rostral/caudal stumps	38252
@NP	OEC	38252
@NP	the rostral/caudal stumps	38275
@NP	a less hostile environment	38321
@NP	The recombinant Ad we used	38349
@NP	The recombinant Ad	38349
@NP	we	38368
@NP	the first generation	38380
@NP	the expression of the encoding gene	38405
@NP	the expression	38405
@NP	the encoding gene	38423
@NP	AdGFP or AdPGIS used in this study	38456
@NP	AdGFP or AdPGIS	38456
@NP	this study	38480
@NP	a phosphoglycerate kinase promoter	38517
@NP	transgene expression	38569
@NP	less immune reaction	38595
@NP	There	38617
@NP	no significant side effects in SCI rats	38628
@NP	no significant side effects	38628
@NP	SCI rats	38659
@NP	Ad transduced cells	38673
@NP	Ad	38673
@NP	cells	38687
@NP	Acute SCI	38694
@NP	a devastating event	38707
@NP	a secondary degenerative process	38731
@NP	acute SCI	38787
@NP	The secondary cascade	38798
@NP	hours and days	38832
@NP	the initial insults	38853
@NP	further neurological damage	38886
@NP	Intervention to block secondary pathological cascade after injury	38915
@NP	secondary pathological cascade	38937
@NP	injury	38974
@NP	cells	38993
@NP	function	39012
@NP	The grafted PGIS-OEC in the injured cords	39022
@NP	The grafted PGIS-OEC	39022
@NP	the injured cords	39046
@NP	PGIS	39091
@NP	up to 3 weeks	39097
@NP	prostacyclin synthesis	39127
@NP	its neuroprotective and anti-inflammatory effects	39162
@NP	the present study	39216
@NP	axon regeneration	39235
@NP	two axonal systems	39269
@NP	-LRB- i -RRB-	39289
@NP	corticospinaltract	39304
@NP	CST	39324
@NP	anterograde axonal tract tracer WGAHRP	39343
@NP	anterograde	39343
@NP	axonal tract tracer WGAHRP	39355
@NP	serotonergic -LRB- 5-HT -RRB- tract , visualized by immunohistochemistry	39402
@NP	serotonergic -LRB- 5-HT -RRB- tract	39402
@NP	5-HT	39416
@NP	immunohistochemistry	39443
@NP	WGA-HRP	39465
@NP	the hindlimb area of the sensory motor cortex	39507
@NP	the hindlimb area	39507
@NP	the sensory motor cortex	39528
@NP	The main pathway of controlling motor in spinal cord	39554
@NP	The main pathway	39554
@NP	controlling motor in spinal cord	39574
@NP	controlling motor	39574
@NP	spinal cord	39595
@NP	the corticospinal tracts of primary motor cortex	39627
@NP	the corticospinal tracts	39627
@NP	primary motor cortex	39655
@NP	Caudal axons labeled by WGA-HRP	39677
@NP	Caudal axons	39677
@NP	WGA-HRP	39701
@NP	thoracic level	39730
@NP	12	39745
@NP	two of the AdPGIS-OEC grafted animals -LRB- ~ 40 % -RRB-	39769
@NP	two	39769
@NP	the AdPGIS-OEC grafted animals -LRB- ~ 40 % -RRB-	39776
@NP	the AdPGIS-OEC	39776
@NP	animals -LRB- ~ 40 % -RRB-	39799
@NP	animals	39799
@NP	~ 40 %	39808
@NP	The WGA-HRP-labeled axons	39815
@NP	the original pathway , between gray matter and white matter	39852
@NP	the original pathway	39852
@NP	between gray matter	39874
@NP	white matter	39898
@NP	we	39921
@NP	any regenerated axons	39939
@NP	the edge of white matter of spinal cord	39972
@NP	the edge	39972
@NP	white matter of spinal cord	39984
@NP	white matter	39984
@NP	spinal cord	40000
@NP	the study of Ramon-Cueto et al. -LSB- 16 -RSB-	40031
@NP	the study	40031
@NP	Ramon-Cueto et al. -LSB- 16 -RSB-	40044
@NP	Ramon-Cueto et al. -LSB-	40044
@NP	the other hand	40072
@NP	the decending serotonergic fibers	40088
@NP	dorsal horn , medicinerea and ventral horn	40142
@NP	dorsal horn	40142
@NP	medicinerea	40155
@NP	ventral horn	40171
@NP	spinal cord -LSB- 49 -RSB-	40187
@NP	spinal cord	40187
@NP	49 -RSB-	40200
@NP	It	40205
@NP	sensory , motor and autonomic functions via serotonin receptors -LSB- 48 -RSB-	40225
@NP	sensory	40225
@NP	motor	40234
@NP	autonomic functions via serotonin receptors -LSB- 48 -RSB-	40244
@NP	autonomic functions	40244
@NP	serotonin receptors -LSB- 48 -RSB-	40268
@NP	serotonin receptors	40268
@NP	48 -RSB-	40289
@NP	the 5-HT neurons projecting to ventral horn	40308
@NP	the 5-HT neurons	40308
@NP	ventral horn	40339
@NP	the functional recovery	40367
@NP	spinal cord injury -LSB- 50 -RSB-	40397
@NP	spinal cord injury	40397
@NP	50 -RSB-	40417
@NP	Raphe nuclei	40422
@NP	the only source of serotonergic fibers	40440
@NP	the only source	40440
@NP	serotonergic fibers	40459
@NP	Thirty days	40480
@NP	complete spinal cord transection	40498
@NP	the caudal stumps of the spinal cord tissue	40532
@NP	the caudal stumps	40532
@NP	the spinal cord tissue	40553
@NP	HT	40606
@NP	2 -RSB-	40610
@NP	immunohistochemistrical staining of 5-HT	40620
@NP	immunohistochemistrical staining	40620
@NP	5-HT	40656
@NP	serotonergic axons	40689
@NP	the lesion site	40728
@NP	the caudal stumps of the spinal cord	40756
@NP	the caudal stumps	40756
@NP	the spinal cord	40777
@NP	the present study	40797
@NP	regenerating 5-HT	40816
@NP	+	40835
@NP	the distal stump	40863
@NP	one -LRB- 16.7 % -RRB- of OEC-grafted and three -LRB- 60 % -RRB- of AdPGISOEC	40883
@NP	one -LRB- 16.7 % -RRB- of OEC-grafted	40883
@NP	one -LRB- 16.7 % -RRB-	40883
@NP	one	40883
@NP	16.7 %	40888
@NP	OEC-grafted	40898
@NP	three -LRB- 60 % -RRB- of AdPGISOEC	40914
@NP	three -LRB- 60 % -RRB-	40914
@NP	three	40914
@NP	60 %	40921
@NP	AdPGISOEC	40929
@NP	SCI rats	40947
@NP	the non-treated SCI animals	40960
@NP	there	40989
@NP	no serotonergic axonal regeneration found in the distal stump -LRB- 0 % -RRB-	40999
@NP	no serotonergic axonal regeneration	40999
@NP	the distal stump -LRB- 0 % -RRB-	41044
@NP	the distal stump	41044
@NP	0 %	41062
@NP	addition	41070
@NP	all regenerating axons	41080
@NP	the gray matter of distal spinal cord	41124
@NP	the gray matter	41124
@NP	distal spinal cord	41143
@NP	more glial cells	41173
@NP	the white matter	41204
@NP	regeneration of injured nerve tracts	41251
@NP	regeneration	41251
@NP	injured nerve tracts	41267
@NP	OEC graft study in Lu et al. -LSB-	41301
@NP	OEC graft study	41301
@NP	Lu et al. -LSB-	41320
@NP	51 -RSB-	41331
@NP	+	41354
@NP	axon in the distal spinal cord , from 3.6 mm to the farthest 6 mm , the 5-HT	41357
@NP	axon	41357
@NP	the distal spinal cord	41365
@NP	3.6 mm to the farthest 6 mm , the 5-HT	41394
@NP	3.6 mm to the farthest 6 mm	41394
@NP	3.6 mm	41394
@NP	the farthest 6 mm	41404
@NP	the farthest	41404
@NP	the 5-HT	41423
@NP	+	41433
@NP	axon found in the present study	41436
@NP	axon	41436
@NP	the present study	41450
@NP	1 mm	41494
@NP	the transected site	41504
@NP	the amount	41529
@NP	We	41554
@NP	it	41568
@NP	the different transection gap between two stumps in the experiment	41586
@NP	the different transection gap	41586
@NP	two stumps in the experiment	41624
@NP	two stumps	41624
@NP	the experiment	41638
@NP	we	41657
@NP	the distance in between two stumps	41667
@NP	the distance	41667
@NP	between two stumps	41683
@NP	the growing distance of the axon	41708
@NP	the growing distance	41708
@NP	the axon	41732
@NP	BBB scale -LSB- 40 -RSB-	41759
@NP	BBB scale	41759
@NP	40 -RSB-	41770
@NP	the motor functional recovery level of the hind limbs in rats	41802
@NP	the motor functional recovery level	41802
@NP	motor	41806
@NP	the hind limbs in rats	41841
@NP	the hind limbs	41841
@NP	rats	41859
@NP	SCI	41870
@NP	The advantage of it	41875
@NP	The advantage	41875
@NP	it	41892
@NP	it	41904
@NP	the animals used in the experiment	41931
@NP	the animals	41931
@NP	the experiment	41951
@NP	advance	41996
@NP	The behavioral result observed in the present study	42005
@NP	The behavioral result	42005
@NP	the present study	42039
@NP	there	42069
@NP	no difference between groups	42079
@NP	no difference	42079
@NP	groups	42101
@NP	the fourth week postinjury	42114
@NP	the sixth week	42148
@NP	the difference	42164
@NP	the groups	42196
@NP	transplanted OEC or Ad-PGIS-OEC and the control group	42212
@NP	transplanted OEC or Ad-PGIS-OEC	42212
@NP	the control group	42248
@NP	We	42267
@NP	it	42284
@NP	the transected interval -LRB- 5 mm -RRB- between two stumps in the experiment	42302
@NP	the transected interval -LRB- 5 mm -RRB-	42302
@NP	the transected interval	42302
@NP	5 mm	42327
@NP	two stumps in the experiment	42341
@NP	two stumps	42341
@NP	the experiment	42355
@NP	It	42371
@NP	about 4	42385
@NP	6 weeks for the axon to grow across this interval	42393
@NP	6 weeks	42393
@NP	the axon to grow across this interval	42405
@NP	this interval	42429
@NP	the average BBB score	42451
@NP	1 point	42490
@NP	4 weeks	42505
@NP	the sixth week	42520
@NP	it	42536
@NP	significant progress	42548
@NP	addition	42573
@NP	we	42583
@NP	none of the animals	42597
@NP	none	42597
@NP	the animals	42605
@NP	coordinate movement between fore and hind limbs	42621
@NP	coordinate movement	42621
@NP	fore and hind limbs	42649
@NP	this twelve-week behavior observation	42672
@NP	the hind limbs	42715
@NP	the weight	42745
@NP	Ramon-Cueto et al. -LSB- 16 -RSB-	42757
@NP	Ramon-Cueto et al. -LSB-	42757
@NP	OEC	42790
@NP	two stumps of transected spinal cord	42799
@NP	two stumps	42799
@NP	transected spinal cord	42813
@NP	the function of hind limbs	42851
@NP	the function	42851
@NP	hind limbs	42867
@NP	the weight	42919
@NP	sevenmonth behavior observation	42936
@NP	the functional recovery	42981
@NP	limit in this twelve-week study	43009
@NP	limit	43009
@NP	this twelve-week study	43018
@NP	the functional recovery	43042
@NP	we	43090
@NP	longer survival	43104
@NP	observation period	43120
@VP	ensheathe bundles of olfactory nerves	232
@VP	have been reported as a favorable substrate for axonal regeneration	271
@VP	been reported as a favorable substrate for axonal regeneration	276
@VP	reported as a favorable substrate for axonal regeneration	281
@VP	to facilitate axonal regeneration although the functional recovery is limited	384
@VP	facilitate axonal regeneration although the functional recovery is limited	387
@VP	is limited	451
@VP	to improve the growth-promoting properties of OEC	477
@VP	improve the growth-promoting properties of OEC	480
@VP	is a vasodilator , platelet anti-aggregatory and cytoprotective agent	720
@VP	Cultured OEC expressed high level of cyclooxygneases , but not PGIS	799
@VP	expressed high level of cyclooxygneases , but not PGIS	812
@VP	could selectively augument prostacyclin synthesis	894
@VP	augument prostacyclin synthesis	912
@VP	cocultured with either OEC or AdPGIS-OEC	950
@VP	were resistant to OGD-induced damage	1007
@VP	transected cavity of thoracic spinal cord injured -LRB- SCI -RRB- rats	1095
@VP	injured -LRB- SCI -RRB- rats	1137
@VP	transplanted SCI rats compared with nontreated SCI rats	1258
@VP	transplanted SCI rats	1352
@VP	showed significantly better motor restoration than OEC transplanted SCI rats	1374
@VP	were found in 40 -- 60 % of AdPGIS-OEC transplanted SCI rats	1522
@VP	found in 40 -- 60 % of AdPGIS-OEC transplanted SCI rats	1527
@VP	transplanted SCI rats	1557
@VP	Enhanced synthesis of prostacyclin in grafted OEC	1593
@VP	injured rats	1719
@VP	are relevant for neural transplant therapies	1841
@VP	does not apply to the olfactory bulb	2240
@VP	apply to the olfactory bulb	2249
@VP	provide support	2532
@VP	cross the transition zone between PNS and CNS	2604
@VP	extend processes in the olfactory bulb without inhibition -LSB- 9 -- 12 -RSB-	2654
@VP	induced a less severe host astrocyte response than Schwann cells -LSB- 18 -RSB-	2876
@VP	is limited -LSB- 14 , 19 , 20 -RSB-	3081
@VP	seems a promising strategy to promote regeneration of injured axon	3146
@VP	to promote regeneration of injured axon	3173
@VP	promote regeneration of injured axon	3176
@VP	promoting effect of OEC	3259
@VP	enhancing prostacyclin synthesis	3394
@VP	acts as a primary vasodilator	3465
@VP	is deacylated from cellular phospholipids -LSB- 23 -RSB-	3708
@VP	deacylated from cellular phospholipids -LSB- 23 -RSB-	3711
@VP	were rapidly produced following tissue injury or inflammation -LSB- 24 -RSB-	3785
@VP	produced following tissue injury or inflammation -LSB- 24 -RSB-	3798
@VP	reported to reduce infarct volume in ischemic rat brains -LSB- 25 , 26 -RSB-	3895
@VP	to reduce infarct volume in ischemic rat brains -LSB- 25 , 26 -RSB-	3904
@VP	reduce infarct volume in ischemic rat brains -LSB- 25 , 26 -RSB-	3907
@VP	reduced the cortical lesion in rats with traumatic brain injury -LSB- 27 -RSB-	4007
@VP	facilitate axonal remodeling of injured neuronal networks	4325
@VP	sprouting of CST fibers , contributing to the repair process -LSB- 30 -RSB-	4395
@VP	sprouting of CST fibers	4395
@VP	contributing to the repair process -LSB- 30 -RSB-	4420
@VP	test the possibility that prostacyclin contributes to spinal nerve regeneration	4603
@VP	contributes to spinal nerve regeneration	4642
@VP	allowing for stable delivery of individual gene in infected cells	4805
@VP	Reagents and antibodies Cultured medium , fetal bovine serum -LRB- FBS -RRB-	5383
@VP	Cultured medium	5407
@VP	were purchased from Invitrogen -LRB- Carlsbad , CA , USA -RRB-	5488
@VP	purchased from Invitrogen -LRB- Carlsbad , CA , USA -RRB-	5493
@VP	were from BD Bioscience -LRB- San Jose , CA , USA -RRB-	5564
@VP	were from Millipore -LRB- Watford , UK -RRB-	5635
@VP	used in the present study were	5689
@VP	were	5715
@VP	stated otherwise	6038
@VP	were purchased from Sigma-Aldrich Co.	6076
@VP	purchased from Sigma-Aldrich Co.	6081
@VP	followed the method described in Nash et al. , -LSB- 34 -RSB- with modification	6193
@VP	described in Nash et al. , -LSB- 34 -RSB- with modification	6213
@VP	were dissected and cleaned of all meninges and blood vessels	6346
@VP	dissected and cleaned of all meninges and blood vessels	6351
@VP	were minced , triturated and trypsinized	6420
@VP	minced , triturated and trypsinized	6425
@VP	dissociated cells	6491
@VP	seeded to uncoated dishes	6514
@VP	supplemented with 10 % FBS for 48 h -LRB- at 37 Â°C and 5 % CO2 -RRB-	6594
@VP	then collected	6677
@VP	reseeded to poly-D-lysine-coated dishes	6693
@VP	supplemented with 10 % FBS and astrocyteconditioned medium -LRB- ACM -RRB-	6760
@VP	were prepared as described in our recent articles -LSB- 29 , 35 -RSB-	6836
@VP	prepared as described in our recent articles -LSB- 29 , 35 -RSB-	6841
@VP	described in our recent articles -LSB- 29 , 35 -RSB-	6853
@VP	refilled with fresh medium and ACM every 2 days until they reached confluence	7013
@VP	reached confluence	7072
@VP	seeding to insert well	7178
@VP	to insert well	7186
@VP	insert well	7189
@VP	to synthesize eicosanoids from AA or for transplantation to SCI rats	7321
@VP	synthesize eicosanoids from AA or for transplantation to SCI rats	7324
@VP	17 days as described in Tsai et al. -LSB- 36 , 37	7567
@VP	plated onto poly-D - lysine-coated dishes in DMEM supplemented with 10 % FBS	7720
@VP	supplemented with 10 % FBS	7769
@VP	were incubated at 37 Â°C in a water-saturated atmosphere of 5 % CO2/95 % air	7806
@VP	incubated at 37 Â°C in a water-saturated atmosphere of 5 % CO2/95 % air	7811
@VP	replaced with glucose-free DMEM	7923
@VP	placed into an air-tight chamber to obtain 0.5 %	7959
@VP	to obtain 0.5 %	7992
@VP	obtain 0.5 %	7995
@VP	was simulated by replacing the exposure medium with normal growth medium	8074
@VP	replacing the exposure medium with normal growth medium	8091
@VP	were then co-cultured with none , OEC or AdPGIS-OEC at 0 h after OGD reperfusion	8157
@VP	co-cultured with none , OEC or AdPGIS-OEC at 0 h after OGD reperfusion	8167
@VP	cells were obtained under a fluorescent microscope	8402
@VP	were obtained under a fluorescent microscope	8408
@VP	obtained under a fluorescent microscope	8413
@VP	equipped with a cooling digital imaging system	8453
@VP	obtained using a 20x object lens	8572
@VP	using a 20x object lens	8581
@VP	using Image-Pro plus software -LRB- NIH systems , Bethesda , MD , USA -RRB-	8620
@VP	were used	8781
@VP	used	8786
@VP	used phosphoglycerate kinase -LRB- PGK -RRB- as a driving promoter	8821
@VP	containing the promoter only without encoding gene	8886
@VP	encoding gene	8923
@VP	was used as a vector control	8938
@VP	used as a vector control	8942
@VP	was utilized for optimizing the infection conditions	8974
@VP	utilized for optimizing the infection conditions	8978
@VP	optimizing the infection conditions	8991
@VP	encoding none , GFP , or PGIS	9094
@VP	was performed as described in previous articles -LSB- 28 , 29 -RSB-	9122
@VP	performed as described in previous articles -LSB- 28 , 29 -RSB-	9126
@VP	described in previous articles -LSB- 28 , 29 -RSB-	9139
@VP	resulting in transduction of virtually all cultured cells	9257
@VP	cultured cells	9300
@VP	was used for infection to cultured OEC ex vivo	9353
@VP	used for infection to cultured OEC ex vivo	9357
@VP	to cultured OEC ex vivo	9376
@VP	cultured OEC ex vivo	9379
@VP	being infected with AdPGK , AdGFP or AdPGIS ex vivo	9448
@VP	infected with AdPGK , AdGFP or AdPGIS ex vivo	9454
@VP	Cultured OEC after recombinant adenoviral infection for 2	9579
@VP	described in our recent articles -LSB- 28 , 29 -RSB-	9737
@VP	containing 10 Î¼M -LSB- 1-14C -RSB- AA at 37 Â°C for 10 min	9845
@VP	resulted cells were harvested for western blot analysis	9898
@VP	were harvested for western blot analysis	9913
@VP	harvested for western blot analysis	9918
@VP	containing released eicosanoids	9969
@VP	released eicosanoids	9980
@VP	were saved for analysis of -LSB- 1-14C -RSB- labeled AA metabolites	10002
@VP	saved for analysis of -LSB- 1-14C -RSB- labeled AA metabolites	10007
@VP	saved for analysis of -LSB- 1-14C	10007
@VP	labeled AA metabolites	10037
@VP	equipped with an on-line radioisotopic detector -LRB- Packard 150-TP -RRB-	10189
@VP	followed methods described previously -LSB- 29 , 32 -RSB-	10254
@VP	described previously -LSB- 29 , 32 -RSB-	10271
@VP	identified by their retention times with the authentic radioisotopic standands	10331
@VP	obtained from NYU Animal Breeding and Research Center in Taiwan	10455
@VP	were used for the present study	10520
@VP	used for the present study	10525
@VP	to minimize animal suffering during and following surgery	10807
@VP	minimize animal suffering during and following surgery	10810
@VP	to reduce the numbers of animals that were sacrificed	10869
@VP	reduce the numbers of animals that were sacrificed	10872
@VP	were sacrificed	10907
@VP	sacrificed	10912
@VP	described protocols -LSB- 36 , 38 , 39 -RSB-	10998
@VP	was made at the thoracic vertebral level 8 -LRB- T8 -RRB-	11250
@VP	made at the thoracic vertebral level 8 -LRB- T8 -RRB-	11254
@VP	were severed along with the dura mater	11323
@VP	severed along with the dura mater	11328
@VP	transected with a 5 mm segment of spinal cord encompassing T8 being removed	11394
@VP	being removed	11456
@VP	removed	11462
@VP	lifted after removal of the spinal cord segment to ensure complete discontinuity	11506
@VP	to ensure complete discontinuity	11554
@VP	ensure complete discontinuity	11557
@VP	Transplanted cells	11588
@VP	were applied to the transected cavity	11650
@VP	applied to the transected cavity	11655
@VP	transected cavity	11670
@VP	were closed separately	11721
@VP	closed separately	11726
@VP	was applied in experimental rats twice daily	11764
@VP	applied in experimental rats twice daily	11768
@VP	were conducted biweekly after transplantation	11849
@VP	conducted biweekly after transplantation	11854
@VP	postgrafting	11908
@VP	were processed for anterograde tracing or for immunohistochemical staining	11940
@VP	processed for anterograde tracing or for immunohistochemical staining	11945
@VP	tracing	11971
@VP	tracing using WGA-horseradish peroxidase	12059
@VP	using WGA-horseradish peroxidase	12067
@VP	was conducted in experimental rats at 12 week after surgery and transplantation	12106
@VP	conducted in experimental rats at 12 week after surgery and transplantation	12110
@VP	were performed over a 3 min period	12366
@VP	performed over a 3 min period	12371
@VP	kept in place for an additional 3 min to minimize leakage on needle withdrawal	12431
@VP	to minimize leakage on needle withdrawal	12469
@VP	minimize leakage on needle withdrawal	12472
@VP	were closed in layers	12553
@VP	closed in layers	12558
@VP	kept for 2 days before processing for tracer identification in spinal cords	12594
@VP	processing for tracer identification in spinal cords	12617
@VP	postfixed in 4 % paraformaldehyde overnight	13057
@VP	cryoprotected in PBS containing 30 % -LRB- w/v -RRB- sucrose for 3 days	13110
@VP	containing 30 % -LRB- w/v -RRB- sucrose for 3 days	13131
@VP	then cross-sectioned at 20 Î¼m thickness with a cryostat	13269
@VP	were processed for immunohistochemistry	13378
@VP	processed for immunohistochemistry	13383
@VP	followed method described in our recent articles -LSB- 35 , 39 -RSB-	13418
@VP	described in our recent articles -LSB- 35 , 39 -RSB-	13434
@VP	followed by respective 2nd antibodies for histological evaluation as described	13537
@VP	described	13606
@VP	used	14000
@VP	performed for all immunostaining protocols to control for nonspecific binding	14250
@VP	to control for nonspecific binding	14293
@VP	control for nonspecific binding	14296
@VP	40 -RSB- as described in our recent articles -LSB- 36 , 39 -RSB-	14607
@VP	cultured cells	15003
@VP	washed twice with PBS	15023
@VP	was quantified by a Biorad protein assay reagent	15233
@VP	quantified by a Biorad protein assay reagent	15237
@VP	described -LSB- 35 , 41	15408
@VP	transferred to PVDF membranes -LRB- Millipore Corp. , USA -RRB-	15461
@VP	Â± s.e.m.	15985
@VP	using one-way analysis of variance -LRB- ANOVA -RRB- followed by LSD test	16012
@VP	followed by LSD test	16055
@VP	were considered to show statistical significance	16096
@VP	considered to show statistical significance	16101
@VP	to show statistical significance	16112
@VP	show statistical significance	16115
@VP	tracing	16444
@VP	was conducted from motor cortex in experimental rats	16452
@VP	conducted from motor cortex in experimental rats	16456
@VP	fibers were found in the thoracic level 12 in two Tx + AdPGIS-OEC Tp rats	16514
@VP	were found in the thoracic level 12 in two Tx + AdPGIS-OEC Tp rats	16521
@VP	found in the thoracic level 12 in two Tx + AdPGIS-OEC Tp rats	16526
@VP	are counterstained with Hoechst 33258 -LRB- blue -RRB-	17099
@VP	counterstained with Hoechst 33258 -LRB- blue -RRB-	17103
@VP	= 50 Î¼m	17149
@VP	are expressed as average Â± SD	17163
@VP	expressed as average Â± SD	17167
@VP	performed in triplicate -LRB- n = 6 per experimental conditions -RRB-	17250
@VP	cultured OEC	17459
@VP	denotes	17644
@VP	cultured OEC receiving AdPGK or AdPGIS infection	17860
@VP	receiving AdPGK or AdPGIS infection	17873
@VP	was conducted at 3 days after Ads transduction	17996
@VP	conducted at 3 days after Ads transduction	18000
@VP	were pulsed with -LSB- 1-14C -RSB- AA for 10 min	18067
@VP	purified	18175
@VP	subsequently analyzed by HPLC with a radiochemical flowthrough detector	18188
@VP	Note that OEC constitutively expressed COX-1 and COX-2 but not PGIS	18261
@VP	expressed COX-1 and COX-2 but not PGIS	18290
@VP	= 100 Î¼m	18886
@VP	compared to neuron-glial cultures	18916
@VP	were expressed as mean Â± SEM	19009
@VP	expressed as mean Â± SEM	19014
@VP	represent the results of three	19039
@VP	enhanced neuronal connection	19175
@VP	reduced microglial number in spinal cord neuron-glial cultures	19208
@VP	cocultured with PGISOEC , -LRB- g & h -RRB-	19396
@VP	-LRB- + -RRB- cell numbers , respectively	19491
@VP	are tubulin immunoreactive cells	19527
@VP	tubulin immunoreactive cells	19531
@VP	are ED1 -LRB- + -RRB- microglial cells	19568
@VP	ED1 -LRB- + -RRB- microglial cells	19572
@VP	= 100 Î¼m	19602
@VP	were expressed as mean Â± SEM	19728
@VP	expressed as mean Â± SEM	19733
@VP	performed in duplicate-triplicate Fig.	19811
@VP	expressing OEC	20016
@VP	depicted -LRB- EDF -RRB-	20035
@VP	c : Transplantation of fibrin glue-mixed OEC to the transection cavity	20124
@VP	= 50 Î¼m	20482
@VP	mediated gene transfer before transplantation	20542
@VP	Note	20589
@VP	marked with star in e & f	20727
@VP	OEC migrated to both stumps at 4	20785
@VP	Grafted AdGFP-OEC	20867
@VP	transected gap	21101
@VP	f : caudal stumps	21121
@VP	shows Iba1 positive microglia	21230
@VP	receiving OEC or AdPGIS-OEC transplant after transection spinal cord injury	21417
@VP	receiving none , OEC graft or AdPGIS-OEC graft , -LRB- c -RRB-	21581
@VP	receiving none , OEC graft or AdPGIS-OEC graft	21655
@VP	induced functional recovery after a complete transection in spinal cord	21717
@VP	were analyzed by ANOVA followed by LSD test	22055
@VP	analyzed by ANOVA followed by LSD test	22060
@VP	followed by LSD test	22078
@VP	labelled signals	22188
@VP	= 50 Î¼m	22385
@VP	using anterograde WGA-HRP tracing from motor sensory cortex	22543
@VP	tracing from motor sensory cortex	22569
@VP	= 100 Î¼m	22608
@VP	are longitudinal sections of proximal cord	22626
@VP	indicate the separation between grey and white matter in panel a.	22686
@VP	indicate 5-HT -LRB- + -RRB- fibers	22758
@VP	5-HT -LRB- + -RRB- fibers in the gray matter of OEC-transplanted distal cords	22795
@VP	are transverse sections of T7 -LRB- proximal -RRB- and T12 -LRB- distal -RRB-	22945
@VP	have successfully established OEC culture from adult rat olfactory bulb	23028
@VP	established OEC culture from adult rat olfactory bulb	23046
@VP	grown to confluence	23107
@VP	were subcultured and processed for immunocytochemistry	23132
@VP	subcultured and processed for immunocytochemistry	23137
@VP	compared to Hoechst 33258 -LRB- + -RRB- cells	23401
@VP	was test using AdGFP infection	23493
@VP	test using AdGFP infection	23497
@VP	using AdGFP infection	23502
@VP	resulting in transduction of virtually all cultured cells -LRB- Fig. 1d -RRB-	23569
@VP	cultured cells -LRB- Fig. 1d -RRB-	23612
@VP	indicates that OEC are highly permissive to AdGFP infection	23643
@VP	are highly permissive to AdGFP infection	23662
@VP	in cultured OEC	23794
@VP	was chosen to infect cultured OEC for selective eicosanoid production	23836
@VP	chosen to infect cultured OEC for selective eicosanoid production	23840
@VP	to infect cultured OEC for selective eicosanoid production	23847
@VP	infect cultured OEC for selective eicosanoid production	23850
@VP	cultured OEC for selective eicosanoid production	23857
@VP	was used as a -LRB- mock -RRB- vector control	23925
@VP	used as a -LRB- mock -RRB- vector control	23929
@VP	was analyzed	24073
@VP	analyzed	24077
@VP	shown as its hydrolysis product 6-keto - PGF1Î± -LRB- 6KP -RRB-	24380
@VP	could be found in OEC	24433
@VP	be found in OEC	24439
@VP	found in OEC	24442
@VP	alter the metabolic profile of -LSB- 1-14C -RSB- AA -LRB- data not shown -RRB-	24506
@VP	not shown	24554
@VP	were shunted through prostacyclin synthesis on AdPGIS transduction to OEC	24596
@VP	shunted through prostacyclin synthesis on AdPGIS transduction to OEC	24601
@VP	was demonstrated in AdPGIStransduced OEC cultures -LRB- Fig. 2b -RRB-	24735
@VP	demonstrated in AdPGIStransduced OEC cultures -LRB- Fig. 2b -RRB-	24739
@VP	was functionally active in producing prostacyclin from AA	24847
@VP	producing prostacyclin from AA	24874
@VP	revealed that OEC expressed high levels of COX-1 and COX-2 but not PGIS	24943
@VP	expressed high levels of COX-1 and COX-2 but not PGIS	24961
@VP	was increased -LRB- Fig. 2c -RRB-	25056
@VP	increased -LRB- Fig. 2c -RRB-	25060
@VP	underwent 3 h of OGD stress and returned to normoxic condition	25290
@VP	underwent 3 h of OGD stress	25290
@VP	returned to normoxic condition	25322
@VP	seeded in Millicell insert well	25371
@VP	incubated for 2 days	25476
@VP	demonstrated by tubulin-IR , in both OEC and PGIS-OEC co-cultures	25565
@VP	show no difference -LRB- Fig. 3g -RRB-	25883
@VP	cells in both OEC co-culture groups were significantly less than those	25934
@VP	were significantly less than those	25970
@VP	protected neuronal cells from OGD-induced damage	26126
@VP	shown in Fig. 4a-c & g	26294
@VP	were pre-transduced with GFP or PGIS by adenovirus-mediated gene transfer	26891
@VP	were then applied to the	27014
@VP	applied to the	27024
@VP	shown in Fig. 5a-c	27107
@VP	shows a complete transection of T8 with a 5 mm gap	27138
@VP	shows fibrin-mixed OEC was grafted to the transected T8 gap	27198
@VP	was grafted to the transected T8 gap	27221
@VP	grafted to the transected T8 gap	27225
@VP	transected T8 gap	27240
@VP	To trace OEC graft in vivo	27259
@VP	trace OEC graft in vivo	27262
@VP	transplanted SCI rats	27310
@VP	grafted SCI rats	27533
@VP	marked with stars in Fig. 5e & f	27676
@VP	did not migrate into the rostral/caudal stumps of the spinal cord	27725
@VP	migrate into the rostral/caudal stumps of the spinal cord	27733
@VP	Grafted OEC	27893
@VP	might migrate into spinal cord stumps	27905
@VP	migrate into spinal cord stumps	27911
@VP	expected	27947
@VP	OEC was	27965
@VP	was	27969
@VP	To examine the effects of prostacyclin on inflammatory cells	28112
@VP	examine the effects of prostacyclin on inflammatory cells	28115
@VP	injured spinal cords of the AdGFP-OEC-grafted and AdPGIS-OEC-grafted groups	28218
@VP	were compared	28294
@VP	compared	28299
@VP	shown in Fig. 6 Iba1 immunoreactivity	28312
@VP	was found in the transection gap	28456
@VP	found in the transection gap	28460
@VP	grafted spinal cords	28550
@VP	have less immunoreactivity than that of AdGFP-OEC grafted spinal cords	28571
@VP	grafted spinal cords	28621
@VP	To ensure all experimental rats receiving similar degrees of injury	28781
@VP	ensure all experimental rats receiving similar degrees of injury	28784
@VP	receiving similar degrees of injury	28813
@VP	to monitor the rate of their recovery	28853
@VP	monitor the rate of their recovery	28856
@VP	were subjected to hindlimb locomotor functional assessment by BBB and CBS scores	28901
@VP	subjected to hindlimb locomotor functional assessment by BBB and CBS scores	28906
@VP	shown in Fig. 7a	28986
@VP	receiving OEC and AdPGIS-OEC	29138
@VP	observed in SCI rats with vehicle treatment -LRB- BBB scores < 1 -RRB-	29294
@VP	were similar to those shown by our previous studies -LSB- 1 , 2 , 39 -RSB-	29394
@VP	shown by our previous studies -LSB- 1 , 2 , 39 -RSB-	29416
@VP	improved the hindlimb function of SCI rats -LRB- all P < 0.05 -RRB-	29551
@VP	were not different from each other until 12 week post graft -LRB- P < 0.05 -RRB-	29646
@VP	receiving AdPGIS-OEC	29745
@VP	receiving none , OEC graft or AdPGIS-OEC graft at 12 weeks post treatment	29971
@VP	shows CBS scores of these experimental rats	30053
@VP	received OEC or AdPGISOEC transplantation	30158
@VP	achieved better restoration	30200
@VP	grafted SCI rats	30442
@VP	grafted SCI rats -LRB- P < 0.05 -RRB-	30505
@VP	to bear weight on the hind limbs	30636
@VP	bear weight on the hind limbs	30639
@VP	tracing for assessing neural regeneration	30769
@VP	assessing neural regeneration	30781
@VP	regenerating 5-HT fibers in the distal stump of OEC-grafted spinal cord	30953
@VP	transplanted SCI rats -LRB- 60 % -RRB-	31167
@VP	Regarding the WGA anterograde tracing results	31196
@VP	tracing results	31226
@VP	grafted spinal cord	31373
@VP	could be found in the distal stump of transected SCI rats	31561
@VP	be found in the distal stump of transected SCI rats	31567
@VP	found in the distal stump of transected SCI rats	31570
@VP	mediated through Ad gene transfer	31887
@VP	enhanced prostacyclin synthesis and concurrently reduced other eicosanoid levels	31933
@VP	enhanced prostacyclin synthesis	31933
@VP	concurrently reduced other eicosanoid levels	31969
@VP	had good neuroregenerative potential in cortical or spinal neuron-glial cultures	32044
@VP	facilitated axonal regeneration across a 5 mm transection gap	32217
@VP	improved hindlimb function	32283
@VP	further promoted fiber tract regeneration	32374
@VP	significantly improved the functional outcome	32420
@VP	tracing from motor sensory cortex	32607
@VP	Regenerating serotonergic axons in the distal cord	32642
@VP	was found in the transected SCI rats	32809
@VP	found in the transected SCI rats	32813
@VP	were immunoreactive to S100 and p75 , the low affinity nerve growth receptor	32967
@VP	cultured OEC	33217
@VP	derived product	33308
@VP	reported in our recent article -LSB- 29 -RSB-	33402
@VP	released barely detected eicosanoids -LSB- 28 -RSB-	33526
@VP	detected eicosanoids -LSB- 28 -RSB-	33542
@VP	shunted the AA catabolism through synthesis of 6	33615
@VP	was concurrently reduced -LRB- Fig. 2 -RRB-	33754
@VP	reduced -LRB- Fig. 2 -RRB-	33771
@VP	to produce prostacyclin	33892
@VP	produce prostacyclin	33895
@VP	is very unstable with biological half-life time being only 2 -- 3 min	34057
@VP	being only 2 -- 3 min	34105
@VP	could also dilate the blood vessels	34138
@VP	dilate the blood vessels	34149
@VP	showed cytoprotective effects of prostacyclin	34276
@VP	was still not yet clear	34341
@VP	could include the function of removing reactive oxygen species -LSB- 43 -RSB-	34405
@VP	include the function of removing reactive oxygen species -LSB- 43 -RSB-	34411
@VP	removing reactive oxygen species -LSB- 43 -RSB-	34435
@VP	had the function of vasoconstriction and platelet aggregation -LSB- 31 , 44	34590
@VP	could inhibit inflammatory cells from aggregating in the injured tissues	34675
@VP	inhibit inflammatory cells from aggregating in the injured tissues	34681
@VP	aggregating in the injured tissues	34713
@VP	alleviated local inflammatory reaction -LSB- 28 , 29 -RSB-	34752
@VP	was examined by in vitro co-culture with neuron-glial cultures	34840
@VP	examined by in vitro co-culture with neuron-glial cultures	34844
@VP	was observed on OGDtreated cortical neuron-glial cells	34942
@VP	observed on OGDtreated cortical neuron-glial cells	34946
@VP	reduced cell death and enhanced neuronal survival	35040
@VP	reduced cell death	35040
@VP	enhanced neuronal survival	35063
@VP	might render them potential clinical agents able to support injured CNS	35115
@VP	render them potential clinical agents able to support injured CNS	35121
@VP	to support injured CNS	35164
@VP	support injured CNS	35167
@VP	enhanced neuronal connection significantly better than OEC	35251
@VP	was significantly reduced by PGIS-OEC co-cultures	35367
@VP	reduced by PGIS-OEC co-cultures	35385
@VP	grafted spinal cords	35441
@VP	may be , in part , mediated through increase of celllar cAMP	35949
@VP	be , in part , mediated through increase of celllar cAMP	35953
@VP	mediated through increase of celllar cAMP	35966
@VP	Reducing microglial activation/infiltration by prostacyclin	36009
@VP	is involved in these effects	36311
@VP	involved in these effects	36314
@VP	played by downstream molecules in the inhibition of microglial number/activation	36390
@VP	suffered from spinal cord injury	36488
@VP	to evaluate the effect of the experimental therapy	36725
@VP	evaluate the effect of the experimental therapy	36728
@VP	was completely transected with 5 mm segment of the spinal cord being removed	36817
@VP	transected with 5 mm segment of the spinal cord being removed	36832
@VP	being removed	36880
@VP	removed	36886
@VP	to inject OEC into stumps since the distance between two stumps was 5 mm	36919
@VP	inject OEC into stumps since the distance between two stumps was 5 mm	36922
@VP	was 5 mm	36983
@VP	could be used as a bridge to connect CNS tissue -LSB- 46 -RSB-	37005
@VP	be used as a bridge to connect CNS tissue -LSB- 46 -RSB-	37011
@VP	used as a bridge to connect CNS tissue -LSB- 46 -RSB-	37014
@VP	to connect CNS tissue -LSB- 46 -RSB-	37031
@VP	connect CNS tissue -LSB- 46 -RSB-	37034
@VP	was employed to enwrap the transplanted OEC and reconnect two spinal stumps	37093
@VP	employed to enwrap the transplanted OEC and reconnect two spinal stumps	37097
@VP	to enwrap the transplanted OEC and reconnect two spinal stumps	37106
@VP	enwrap the transplanted OEC and reconnect two spinal stumps	37109
@VP	enwrap the transplanted OEC	37109
@VP	reconnect two spinal stumps	37141
@VP	embedded in fibrin glue	37178
@VP	could help new regenerating axon re-grow into the distal stump of spinal cord	37202
@VP	help new regenerating axon re-grow into the distal stump of spinal cord	37208
@VP	migrate in the host spinal cord together with growing axon -LSB- 17 , 47 -RSB-	37329
@VP	growing axon -LSB- 17 , 47 -RSB-	37375
@VP	could survive and migrate in the host spinal cord	37447
@VP	survive and migrate in the host spinal cord	37453
@VP	applied AdGFP gene transfer to OEC before cell grafting	37501
@VP	expressing GFP	37585
@VP	could be found at one and three weeks after surgery	37600
@VP	be found at one and three weeks after surgery	37606
@VP	found at one and three weeks after surgery	37609
@VP	distributed inside the transplanted site and the edge of the transplanted area	37680
@VP	Grafted OEC	37888
@VP	migrated into spinal cord stumps at three weeks postgraft	37900
@VP	expected	37962
@VP	OEC was found in both rostral/caudal stumps of the spinal cord about 4 -- 5 mm	37980
@VP	was found in both rostral/caudal stumps of the spinal cord about 4 -- 5 mm	37984
@VP	found in both rostral/caudal stumps of the spinal cord about 4 -- 5 mm	37988
@VP	agreed with our previous result -LSB- 34 -RSB-	38127
@VP	migrated into the rostral/caudal stumps	38261
@VP	survived because of a less hostile environment	38301
@VP	used	38371
@VP	was the first generation	38376
@VP	was temporary	38441
@VP	used in this study	38472
@VP	could drive transgene expression with less immune reaction	38557
@VP	drive transgene expression with less immune reaction	38563
@VP	were no significant side effects in SCI rats with Ad transduced cells	38623
@VP	transduced cells	38676
@VP	is a devastating event	38704
@VP	is initiated following acute SCI	38764
@VP	initiated following acute SCI	38767
@VP	occurs over hours and days after the initial insults	38820
@VP	leads to further neurological damage	38877
@VP	to block secondary pathological cascade after injury	38928
@VP	block secondary pathological cascade after injury	38931
@VP	can protect cells and preserve function	38981
@VP	protect cells and preserve function	38985
@VP	protect cells	38985
@VP	preserve function	39003
@VP	increased prostacyclin synthesis	39117
@VP	exerted its neuroprotective and anti-inflammatory effects	39154
@VP	visualized by anterograde axonal tract tracer WGAHRP	39329
@VP	visualized by immunohistochemistry	39429
@VP	was injected stereotaxically into the hindlimb area of the sensory motor cortex	39473
@VP	injected stereotaxically into the hindlimb area of the sensory motor cortex	39477
@VP	was originated from the corticospinal tracts of primary motor cortex	39607
@VP	originated from the corticospinal tracts of primary motor cortex	39611
@VP	labeled by WGA-HRP	39690
@VP	grafted animals -LRB- ~ 40 % -RRB-	39791
@VP	located in the original pathway , between gray matter and white matter	39841
@VP	demonstrated in the study of Ramon-Cueto et al. -LSB- 16 -RSB-	40015
@VP	projecting to ventral horn	40325
@VP	was related to the functional recovery after spinal cord injury -LSB- 50 -RSB-	40352
@VP	related to the functional recovery after spinal cord injury -LSB- 50 -RSB-	40356
@VP	were the only source of serotonergic fibers	40435
@VP	were not immunoreactive to 5 - HT -LSB- 2 -RSB-	40576
@VP	to 5 - HT -LSB- 2 -RSB-	40600
@VP	5 - HT -LSB- 2 -RSB-	40603
@VP	be used to examine if serotonergic axons regenerated through the lesion site	40667
@VP	used to examine if serotonergic axons regenerated through the lesion site	40670
@VP	to examine if serotonergic axons regenerated through the lesion site	40675
@VP	examine if serotonergic axons regenerated through the lesion site	40678
@VP	regenerated through the lesion site	40708
@VP	reached the caudal stumps of the spinal cord	40748
@VP	grafted SCI rats	40939
@VP	found in the distal stump -LRB- 0 % -RRB-	41035
@VP	was not hospitable for regeneration of injured nerve tracts	41228
@VP	found in the present study	41441
@VP	was located not exceeding 1 mm from the transected site	41468
@VP	exceeding 1 mm from the transected site	41484
@VP	was not much	41540
@VP	related to the different transection gap between two stumps in the experiment	41575
@VP	add on the distance in between two stumps	41660
@VP	would be similar	41741
@VP	be similar	41747
@VP	was easy to execute	41907
@VP	to execute	41916
@VP	execute	41919
@VP	used in the experiment	41943
@VP	did not need to be trained in advance	41966
@VP	need to be trained in advance	41974
@VP	to be trained in advance	41979
@VP	be trained in advance	41982
@VP	trained in advance	41985
@VP	observed in the present study	42027
@VP	was no difference between groups until the fourth week postinjury	42075
@VP	to grow across this interval	42414
@VP	grow across this interval	42417
@VP	would not exceed 1 point before 4 weeks	42473
@VP	exceed 1 point before 4 weeks	42483
@VP	had significant progress	42544
@VP	could not bear the weight	42730
@VP	bear the weight	42740
@VP	injected OEC into two stumps of transected spinal cord	42781
@VP	recover and even bear the weight after sevenmonth behavior observation	42897
@VP	recover	42897
@VP	bear the weight after sevenmonth behavior observation	42914
@VP	had limit in this twelve-week study	43005
@VP	could be much better if we could have longer survival observation period	43066
@VP	be much better if we could have longer survival observation period	43072
@VP	could have longer survival observation period	43093
@VP	have longer survival observation period	43099
